

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Priority stratification for precedence colonoscopy based on two-sample faecal immunochemical test (FIT) screening

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2020-046055  |
| Article Type:                 | Original research  |
| Date Submitted by the Author: | 22-Oct-2020  |
| Complete List of Authors:     | Toyoshima, Osamu; Toyoshima Endoscopy Clinic, Gastroenterology; The University of Tokyo, Department of Gastroenterology<br>Yamaji, Yutaka; Tokyo Pharmaceutical Industry Health Insurance Society, Health Development Center<br>Nishizawa, Toshihiro; Toyoshima Endoscopy Clinic, Gastroenterology; International Medical and Welfare College, Department of Gastroenterology and Hepatology<br>Yoshida, Shuntaro; Toyoshima Endoscopy Clinic, Gastroenterology<br>Yamada, Tomoharu; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kurokawa, Ken; The University of Tokyo, Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Obata, Miho; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kondo, Ryo; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Toba, Masahito; Toba Clinic, Gastroenterology<br>Koike, Kazuhiko; The University of Tokyo, Department of Gastroenterology |
| Keywords:                     | Gastrointestinal tumours < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Gastroenterology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT   |
|                               |  |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **ORIGINAL ARTICLE**  
5  
6  
7  
8  
9

10 **TITLE**  
11  
12

13 **Priority stratification for precedence colonoscopy based on two-sample faecal immunochemical**  
14  
15  
16 **test (FIT) screening**  
17  
18  
19  
20  
21

22 **AUTHORS**  
23  
24

25 Osamu Toyoshima, MD<sup>1,2</sup>, Yutaka Yamaji, MD, PhD<sup>3</sup>, Toshihiro Nishizawa, MD, PhD<sup>1,4</sup>, Shuntaro  
26  
27  
28 Yoshida, MD, PhD<sup>1,2</sup>, Tomoharu Yamada, MD, PhD<sup>1,2</sup>, Ken Kurokawa, MD, PhD<sup>1,2</sup>, Miho Obata,  
29  
30  
31 MD<sup>1,2</sup>, Ryo Kondo, MD<sup>1,2</sup>, Masahito Toba, MD, PhD<sup>5</sup>, and Kazuhiko Koike, MD, PhD<sup>2</sup>  
32  
33  
34  
35  
36

37 **Affiliations**  
38  
39

40 <sup>1</sup> Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo, Japan  
41  
42

43 <sup>2</sup> Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo,  
44  
45  
46 Japan  
47  
48

49 <sup>4</sup> Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo,  
50  
51  
52 Japan  
53  
54

55 <sup>4</sup> Department of Gastroenterology and Hepatology, International University of Health and Welfare,  
56  
57  
58 Narita Hospital, Chiba, Japan  
59  
60

1  
2  
3  
4 <sup>5</sup> Gastroenterology, Toba Clinic, Tokyo, Japan  
5  
6  
7  
8  
9

10 **Corresponding Author:** Osamu Toyoshima, MD, Director, Gastroenterology, Toyoshima

11  
12  
13 Endoscopy Clinic.

14  
15  
16 6-17-5 Seijo, Setagaya-ku, Tokyo 157-0066, JAPAN

17  
18  
19 Email: [t@ichou.com](mailto:t@ichou.com); Phone: +81-3-5429-9555; Fax: +81-3-5429-9511  
20  
21  
22  
23  
24

25 **Contributors:** Study concept and design: OT, YY, and KKo. Acquisition, analysis, or interpretation  
26  
27 of data: OT, YY, TN, SY, TY, KKu, MO, RK, and MT. Writing of the manuscript: OT. Critical  
28  
29 revision of the manuscript for important intellectual content: YY, TN, SY, TY, KKu, MO, RK, MT,  
30  
31 and KKo. Statistical analysis: OT and YY. Supervision: KKo. All authors approved the submitted  
32  
33 version of the manuscript.  
34  
35  
36  
37  
38  
39

40 **Competing interests:** None.  
41  
42

43 **Funding:** The authors have not declared a specific grant for this research from any funding agency in the  
44  
45 public, commercial or not-for-profit sectors.  
46  
47  
48

49 **Ethics approval:** [review board] Certificated Review Board, Hattori Clinic (certification no.  
50  
51 CRB3180027), [approval date] September 6th, 2019, [approval no.] S1909-U06, [registration site]  
52  
53 UMIN-CTR system ([https://rctportal.niph.go.jp/en/detail?trial\\_id=UMIN000018541](https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000018541)), [registration  
54  
55 no.] UMIN000018541.  
56  
57  
58  
59  
60

1  
2  
3  
4 **Informed consent statement:** Written informed consents were obtained from the participants.  
5  
6

7 **Patient and public involvement:** Patients and/or the public were involved in the design, or conduct,  
8  
9  
10 or report, or dissemination plans of this research. Information on the publication of this study will be  
11  
12  
13 provided to the patients on the website of our clinic (<https://www.ichou.com>).  
14  
15

16 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
17  
18

19 **Data availability statement:** Data are available upon reasonable request. Additional data can be obtained by  
20  
21  
22 emailing OT at [t@ichou.com](mailto:t@ichou.com). All requests for data sharing should be discussed with OT at the first instance.  
23  
24

25 **STROBE statement:** The authors have read the STROBE Statement checklist of items, and the manuscript  
26  
27  
28 was prepared and revised according to the STROBE Statement checklist of items.  
29  
30

31 **Running title:** Triage by 2-sample FIT  
32  
33

34 **Manuscript word count:** 2466 words  
35  
36

37 **Keywords:** hemoccult; colorectal cancer; colorectal cancer screening; colonoscopy; cancer  
38  
39  
40 prevention  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective** Little has been reported on the yield and characteristics of colorectal neoplasia detected by the 2-sample faecal immunochemical test (FIT), particularly the difference between subjects with 2-positive results on the 2-sample FIT and those with 1-positive results. We aimed to assess risk stratification amongst patients with positive 2-sample FIT to prioritise colonoscopy.

**Design** Consecutive patients who underwent colonoscopy at our institute were enrolled. The indications for colonoscopy included 2-positive results on the 2-sample FIT (FIT (2+)), the other patterns of positive FIT results (FIT (+)), and other reasons (non-FIT group, including presence of symptoms, screening, or surveillance). The detection rates of colorectal cancers, including in situ cancers (all cancers) and invasive cancers, based on the indication for colonoscopy, were investigated.

**Results** Of the 9147 patients, 264 underwent colonoscopy following FIT (2+), 1441 following FIT (+), and 7442 for reasons other than positive FIT. Detection rates of all (and invasive) cancers in the FIT (2+), FIT (+), and non-FIT groups were 12.1% (8.3%), 1.9% (0.5%), and 0.4% (0.2%), respectively. The cancer detection rates were much higher in the FIT (2+) group than in the FIT (+) group, which in turn had higher rates than the non-FIT group. Moreover, the FIT (2+) group showed more advanced T stages on TNM classification (Tis/T1/T2/T3/T4: 10/7/4/10/1) than the FIT (+) group (20/3/2/1/1,  $P<.001$ ).

**Conclusions** 2-positive results for 2-sample FIT showed a much higher yield for more advanced

1  
2  
3  
4 colorectal cancers than the 1-positive result. High priority for diagnostic colonoscopy should be  
5  
6  
7 assigned to patients with 2-positive-FIT results.  
8  
9

10  
11  
12  
13 (252 words)  
14  
15  
16  
17

### 18 **Strengths and limitations of this study**

- 19 ● This study shows real-world data on 2-sample FIT in Japan, where 2-sample FIT-based  
20  
21 colorectal screening has been conducted for many years throughout the country.  
22  
23
- 24 ● This study shows that 2-sample FIT can be useful in triage of patients for diagnostic  
25  
26 colonoscopy depending on the number of positive results.  
27  
28
- 29 ● This study also suggests that 2 positive results from 2-sample FITs may be useful for colorectal  
30  
31 cancer screening in younger patients below 50 years of age.  
32  
33
- 34 ● The cross-sectional design at a single endoscopy clinic was a limitation.  
35  
36
- 37 ● We could not assess the faecal haemoglobin concentration and the patients' symptoms in detail.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## INTRODUCTION

Colorectal cancer is one of the leading cancers worldwide, with 1.8 million new cases and 860,000 deaths annually, and has a significant impact on public health.<sup>1</sup> Screening for colorectal cancer has shown significant effects on reducing the morbidity and mortality, and is also economical.<sup>2</sup> There are several options for colorectal cancer screening, such as primary colonoscopy, sigmoidoscopy, and stool-based tests.<sup>2</sup> Amongst stool-based tests, the faecal immunochemical test (FIT) is now widely used instead of the guaiac faecal occult blood test, because of its higher accuracy and ease of handling.<sup>3,4</sup> Although its accuracy is limited compared to that of primary colonoscopy, FIT is noninvasive and can conserve the resources required for colonoscopy and reduce human contact. Hence, FIT might facilitate the safety and prioritisation of patients during the COVID-19 pandemic.<sup>5</sup>

In Japan, the population-based annual 2-sample FIT has been used for colorectal cancer screening for three decades since 1992.<sup>6</sup> For implementation and effectiveness, the number of FIT samples required, the interval between two FITs, and the FIT brands have been estimated.<sup>4</sup> The 2-sample method has been reported to have the best sensitivity and specificity for colorectal cancer.<sup>3,7</sup> Some investigators also reported that the sensitivity for advanced neoplasia was higher by using the 2-sample method than by the 1-sample method.<sup>8,9</sup>

At least 1-positive result is defined as a positive result in the 2-sample FIT method.<sup>3,7-9</sup> Few studies have investigated the yield and characteristics of neoplasia detected by 2-sample FIT.<sup>8-10</sup> In particular, little is known about the differences between the subjects with 2-positive results in the 2-

1  
2  
3  
4 sample FIT and those with 1-positive result.<sup>11,12</sup> In this study, we investigated the detection rates and  
5  
6  
7 features of invasive and in situ colorectal cancers detected by colonoscopy at our institution based on  
8  
9  
10 the indication for colonoscopy, focussing on the positivity patterns in the 2-sample FIT.  
11  
12  
13  
14  
15

## 16 **METHODS**

### 17 **Study design**

18  
19  
20  
21  
22 This cross-sectional study included consecutive patients who underwent colonoscopy at the  
23  
24  
25 Toyoshima Endoscopy Clinic from April 2017 to August 2019. The indications for colonoscopy  
26  
27  
28 included a positive FIT result, evaluation of symptoms, screening, surveillance, and treatment.  
29  
30  
31 Samples for FIT measurements were collected from two consecutive bowel movements. We divided  
32  
33  
34 the patients who were FIT positive into two categories: FIT (2+) and FIT (+). We defined 2-positive  
35  
36  
37 results for 2 samples as FIT (2+) and the other positive FIT results (i.e., 1-positive result for 1  
38  
39  
40 sample, 1-positive result for 2 samples, or unknown number-positive results for 2 samples) as FIT  
41  
42  
43 (+). The results of FIT were based on the test conducted at our clinic or at the referral medical  
44  
45  
46 institutions. The symptoms included abnormal bowel habits, hematochezia, and abdominal pain. The  
47  
48  
49 surveillance included patients with a medical history of colorectal cancer, colorectal polyps, or  
50  
51  
52 inflammatory bowel diseases. Treatment involved polypectomy and haemostasis. We excluded  
53  
54  
55 colonoscopies performed for treatment from this study. All indications other than positive FIT were  
56  
57  
58 divided into two categories: symptoms and screening + surveillance (asymptomatic).  
59  
60

## Ethics

This study was approved by the Certificated Review Board, Hattori Clinic on September 6th, 2019 (approval no. S1909-U06, registration no. UMIN000018541). Written informed consent was obtained from the patients. All clinical investigations were conducted according to the ethical guidelines of the Declaration of Helsinki.

## Colonoscopy

Colonoscopies were performed by certified gastroenterologists. Olympus Elite 290 endoscope series (Olympus, Tokyo, Japan) was used.<sup>13,14</sup> The clinical data were recorded on an electronic endoscopy reporting system, T-File System (STS Medic, Tokyo, Japan). The data included the patients' baseline characteristics (age, sex, and indication for colonoscopy) and tumour characteristics (location and size).

All colonoscopists were instructed to observe the entire colorectum, with a withdrawal time of 6 minutes or longer.<sup>15,16</sup> Polyps 15 mm in size or smaller were resected at the time of the examination, and if the polyp was larger than 15 mm, or if invasive cancer was suspected, the patient was referred to the hospital.<sup>17</sup>

## Colorectal cancer

Colorectal cancer was treated by endoscopic resection, surgery, chemotherapy, and/or best

1  
2  
3  
4 supportive care. The patients received treatment at our clinic or at the hospital they were referred to.  
5  
6  
7 Colorectal cancer was diagnosed by histopathology. The location of cancer was determined by  
8  
9  
10 colonoscopy, surgery, or CT. The location from the caecum to the transverse colon was defined as  
11  
12  
13 proximal colon. The size of the cancer was measured by colonoscopy, pathology, or CT. The extent  
14  
15  
16 of tumour invasion was determined by pathology in combination with colonoscopy and CT findings.  
17  
18  
19 Tumours were classified according to the T stage of the UICC TNM classification.<sup>18</sup> We included  
20  
21  
22 noninvasive carcinoma (carcinoma in situ) as a cancer.<sup>19</sup> The histological subtype of the cancer was  
23  
24  
25 determined by histopathological evaluation of the resected or biopsy specimens. Four histological  
26  
27  
28 subtypes of adenocarcinomas (i.e., well-differentiated, moderately-differentiated, poorly-  
29  
30  
31 differentiated, and mucinous adenocarcinoma) were classified into two categories: well- +  
32  
33  
34 moderately-differentiated and poorly-differentiated + mucinous adenocarcinoma based on the  
35  
36  
37 prognosis of the subtypes.<sup>20</sup>  
38  
39  
40  
41  
42

### 43 **Outcomes**

44  
45  
46 The main outcomes were detection rates of all colorectal cancers (including carcinomas in situ) and  
47  
48  
49 those of invasive colorectal cancers, based on the indication for colonoscopy. The secondary  
50  
51  
52 outcomes were the features of the cancers, such as location, size, T stage, and histological subtype.  
53  
54  
55 We also divided the patients into 2 groups according to age: <50 years and  $\geq$ 50 years, and analysed  
56  
57  
58 the detection rates and features of the cancers.  
59  
60

## Statistical analysis

The cancer detection rates were compared using the chi-squared test or Fisher's exact test. The characteristics of the cancer were compared using the Mann-Whitney U test, chi-squared test, or Fisher's exact test. The association between the T stages of colorectal cancers and the number of positive results of FIT was analysed using Spearman's rank correlation test. A two-sided *P* value <.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS version 21.0 (IBM SPSS, Armonk, NY).

## Patient and public involvement

Patients and/or the public were involved in the design, or conduct, or report, or dissemination plans of this research. Information on the publication of this study will be provided to the patients on the website of our clinic (<https://www.ichou.com>).

## RESULTS

### Characteristics of the study patients

During the study period, 9321 patients underwent colonoscopy. Of these, 174 patients were excluded because they underwent colonoscopy for treatment. Finally, 9147 patients (age, mean  $\pm$  SD:  $53.6 \pm 12.5$  years; male sex: 49.6%) were eligible for this study. In all, 1705 colonoscopies were

1  
2  
3  
4 performed following positive FIT results. Of the positive FIT results, 264 were FIT (2+) and 1441  
5  
6  
7 were FIT (+). The remaining 7442 colonoscopies performed for indications other than positive FIT  
8  
9  
10 included 1826 for evaluation of the symptoms, and 5616 for screening (2394) + surveillance (3222),  
11  
12  
13 all these were performed without FIT investigation (**Table 1**).

### 14 15 16 17 18 19 **Cancer detection rates based on the indication for colonoscopy**

20  
21  
22 The detection rates of colorectal cancer based on the indication for colonoscopy are shown in  
23  
24  
25 **Table 2**. All colorectal cancers (including carcinoma in situ) and invasive cancers were detected in  
26  
27  
28 1.0% (87/9147 cases) and 0.4% (41 cases) of patients included in the study. The detection rates of all  
29  
30  
31 cancers and invasive cancers in FIT-positive patients were 3.5% (59/1705 cases) and 1.7% (29  
32  
33  
34 cases), which were significantly higher than those detected patients who did not undergo FIT (0.4%  
35  
36  
37 for all cancers, 28/7442,  $P<.001$ ; 0.2% for invasive cancers, 12 cases,  $P<.001$ ).

38  
39  
40 Amongst FIT-positive patients, the rate of detection of all cancers in the FIT (2+) group was very  
41  
42  
43 high at 12.1% (32/264 patients) and that in the FIT (+) group was 1.9% (27/1441 patients). Invasive  
44  
45  
46 cancers accounted for 8.3% (22 cases) in the FIT (2+) group and 0.5% (7 cases) in the FIT (+) group.  
47  
48  
49 FIT (2+) had significantly higher detection rates than FIT (+) ( $P<.001$  and  $P<.001$ ).

50  
51  
52 Amongst patients who did not undergo FIT, the cancer detection rates in symptomatic patients  
53  
54  
55 were significantly higher than in asymptomatic patients, in whom colonoscopy was performed for  
56  
57  
58 screening and surveillance (0.8% and 0.2% for all cancers,  $P<.001$ , 0.4% and 0.1% for invasive  
59  
60

1  
2  
3  
4 cancers,  $P=.01$  respectively).

5  
6  
7 Additionally, the rate of cancer detection was significantly higher in patients with FIT (+) than in  
8  
9  
10 those with symptoms (1.9% and 0.8%,  $P<.001$ ).

### 11 12 13 14 15 16 **Cancer detection rates based on age and FIT positivity groups**

17  
18  
19 **Table 3** shows the rates of detection for colorectal cancer based on age group and FIT positivity  
20  
21  
22 patterns.

23  
24  
25 In patients aged  $\geq 50$  years, the FIT (2+) group showed the highest rate of cancer detection (12.9%  
26  
27  
28 for all cancers and 8.6% for invasive cancers). For the FIT (+) group, the respective rates were 3.5%  
29  
30  
31 and 1.0%, which were significantly lower than those in the FIT (2+) group ( $P<.001$  and  $P<.001$ ),  
32  
33  
34 suggesting that early stage cancers are more predominant.

35  
36  
37 In the  $< 50$  years age group as well, the rate of cancer detection was higher in the FIT (2+) group  
38  
39  
40 (11.3% for all cancers and 8.1% for invasive cancers). They were comparable to those in the  $\geq 50$   
41  
42  
43 age group. However, the rates of detection in FIT (+) group were low (0.4% and 0.0%); moreover,  
44  
45  
46 they were lower than those in the same FIT (+) group at age  $\geq 50$  years ( $P<.001$  and  $P<.001$ ).

### 47 48 49 50 51 52 **The features of the colorectal cancers**

53  
54  
55 **Table 4** shows the features of colorectal cancers based on the indication for colonoscopy. The  
56  
57  
58 colorectal cancers in patients with FIT (2+) were larger than those in the FIT (+) patients (31.2 mm  
59  
60

1  
2  
3  
4 and 21.0 mm,  $P=.006$ ). The T stage of FIT (2+) colorectal cancer was more advanced than that of the  
5  
6  
7 FIT (+) cancers ( $P<.001$ ). Although cancers were generally likely to be located in the distal colon or  
8  
9  
10 rectum, the cancers detected during screening and surveillance colonoscopies were predominantly in  
11  
12  
13 the proximal colon (proximal colon/distal colon and rectum: 7/6 for screening and surveillance vs.  
14  
15  
16 17/57 for the others,  $P=.04$ ).

17  
18  
19 The cancer detection rates stratified by T stage based on age ( $\geq 50$  and  $<50$  years) and FIT  
20  
21  
22 positivity patterns (FIT (2+) and FIT (+)) are shown in **Figure 1**. FIT (2+) patients had  
23  
24  
25 predominantly more advanced cancers than the FIT (+) patients (Tis/T1/T2/T3/T4 for FIT [2+] vs.  
26  
27  
28 FIT [+]: 6/2/3/7/0 vs. 17/3/2/1/1 in  $\geq 50$  years:  $P=.008$ ; 4/5/1/3/1 vs. 3/0/0/0/0 in  $<50$  years:  $P=.04$ ).

## 33 34 **DISCUSSION**

35  
36  
37 This study found that cases with 2-positive FIT results in 2 samples had significantly high rates of  
38  
39  
40 more advanced-stage colorectal cancers amongst all cases with positive FIT results. Although FIT  
41  
42  
43 has been an important screening tool for colorectal cancer and can help in selecting candidates for  
44  
45  
46 diagnostic colonoscopy, patients with 2-positive results were shown to be at the highest risk for life-  
47  
48  
49 threatening cancer. In the face of the COVID-19 pandemic, when resources for colonoscopy are  
50  
51  
52 limited, FIT can stratify the patients' risk. The study outcomes indicate that those with FIT (2+)  
53  
54  
55 should be given the highest priority for colonoscopy.  
56  
57  
58  
59  
60



1  
2  
3  
4 Although the sensitivity of FIT is superior to that of the guaiac test,<sup>3,4</sup> the sensitivity is lower for  
5  
6  
7 early stage cancer or high-grade dysplasia. Morikawa *et al.*<sup>21</sup> compared the results of 1-sample FIT  
8  
9  
10 and total colonoscopy in asymptomatic Japanese patients and reported that the sensitivity for  
11  
12  
13 invasive cancer was 78.3% (18/23) for Dukes' stages C or D, 70.0% (7/10) for Dukes' stage B, and  
14  
15  
16 52.8% (19/36) for Dukes' stage A, and that for high-grade dysplasia was 32.7% (39/119). A similar  
17  
18  
19 study from Taiwan reported that the 1-sample FIT showed a sensitivity of 100% (5/5) for cancers in  
20  
21  
22 T2-4 stages and 66.7% (12/18) for those of Tis or T1.<sup>22</sup> The 2-sample method was adopted to  
23  
24  
25 improve the sensitivity of FIT.<sup>3,7-9</sup>

26  
27  
28 A simulation analysis based on the results of colonoscopic screening in the Japanese subjects  
29  
30  
31 predicted markedly higher positive predictive values (PPVs) for invasive cancers in patients with 2  
32  
33  
34 positive FIT results.<sup>23</sup> The PPVs were estimated to be 1.7% and 26% for male subjects in their 50s  
35  
36  
37 with 1 and 2 positive FITs, respectively. PPVs could increase because of lower rates of false  
38  
39  
40 positivity in cases with 2 positive FITs. The effect of improving the sensitivity could be higher for  
41  
42  
43 early stage lesions than for advanced cancers, for which the sensitivity is already high in single-  
44  
45  
46 sample FIT. One positive result in two samples was predicted to detect predominantly earlier-stage  
47  
48  
49 lesions. Few investigators have reported the actual findings of colonoscopy comparing one and two  
50  
51  
52 positive FITs in 2-sample FIT screening. Our result is compatible with a previous Canadian study,  
53  
54  
55 which reported PPVs for colorectal cancer to be 1% and 8%, in patients with 1 and 2 positive FITs,  
56  
57  
58 respectively.<sup>11</sup> A recent study from the Netherlands suggested that 2-positive FITs from two samples  
59  
60

1  
2  
3  
4 of the same bowel movement also have high cancer detection rates.<sup>12</sup> The present study showed more  
5  
6  
7 advanced stages of colorectal cancers were predominant in patients with 2-positive FITs.  
8  
9

10 The FIT (+) group showed higher rates of cancer detection than those in whom the colonoscopy  
11  
12 was performed for evaluation of symptoms, screening, or surveillance. This might be partly because  
13  
14 the patients' symptoms at our clinic were generally mild. Although further evaluations are necessary,  
15  
16 FIT might be helpful in making decisions about performing colonoscopy in symptomatic patients<sup>24</sup>  
17  
18  
19 or at the time of surveillance for patients after polypectomy.<sup>25</sup>  
20  
21  
22

23  
24  
25 Even in patients <50 years of age, those with FIT (2+) showed negligible rates of colorectal  
26  
27 cancers, and in those with FIT (+), the rates were very low. Our results suggest that patients under 50  
28  
29 years of age with 2 positive FITs might need to receive a higher priority for colonoscopy than those  
30  
31 over 50 years with 1 positive FIT. There is some discussion as to whether colorectal cancer screening  
32  
33 should be started for subjects under 50 years of age, in whom the incidence of colorectal cancer is  
34  
35 quite low but is increasing.<sup>26</sup> If they were screened by 2 positive results from 2 sample FITs, the  
36  
37 cost-benefit balance might be acceptable.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Limitations and Strengths**

50  
51  
52 This study has several limitations. First, it was conducted at a single endoscopy unit; hence, the  
53  
54 results cannot be generalised. However, the indications and quality of colonoscopy as well as the  
55  
56 criteria for diagnosis were well controlled. Two-sample FIT-based colorectal screening has been  
57  
58  
59  
60

1  
2  
3  
4 conducted for many years throughout Japan. Our results could well represent the regular practice of  
5  
6 colorectal screening in Japan. Second, since our institute is specialised in endoscopies, many patients  
7  
8 were referred from other medical institutions for colonoscopy. The category of FIT (+) included  
9  
10 various categories of positivity for FIT: 1-positive result in 2 samples, 1-positive result in 1 sample,  
11  
12 unknown number-positive results in 2 samples, and so on. The brand names of FIT kits or cutoff  
13  
14 values for positivity were also unknown in many cases. However, a similar trend was seen when  
15  
16 patients with 1-positive result in 2 samples from the FIT (+) group were separately analysed  
17  
18 **(Supplemental Table 1)**. Third, we did not assess the patients' symptoms in detail, as cancer  
19  
20 detection rates were low in symptomatic patients without FIT evaluation. However, the symptoms in  
21  
22 our patients were generally mild. In populations with more serious symptoms, they could also be  
23  
24 useful to urge early colonoscopy.<sup>27</sup>

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40 In conclusion, 2-positive results for 2 samples of FIT showed a much higher yield of advanced  
41  
42 colorectal cancers than the 1-positive result, which also showed a higher yield than colonoscopy  
43  
44 performed in patients with symptoms or with an associated history. The highest priority for  
45  
46 diagnostic colonoscopy should be assigned to patients with 2-positive-FIT results.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
2. Segnan N, Patnick J, von Karsa L, eds. *European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis.* 1st ed. Luxembourg: Publications Office of the European Union; 2010.
3. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. *Am J Gastroenterol.* 2010;105(9):2017-2025.
4. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal Immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology.* 2017;152(5):1217-1237.
5. Issaka RB, Somsouk M. Colorectal Cancer Screening and Prevention in the COVID-19 Era [published online May 13, 2020]. *JAMA Health Forum.*
6. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut.* 2015;64(10):1637-1649.

- 1  
2  
3  
4 7. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical  
5  
6  
7 fecal occult blood test for detection of colorectal neoplasia. *Hepatogastroenterology*.  
8  
9  
10 1999;46(25):228-231.  
11
- 12  
13 8. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of  
14  
15  
16 samples and positivity cutoff. What is the best strategy for colorectal cancer screening? *Br J Cancer*.  
17  
18  
19 2009;100(2):259-265.  
20
- 21  
22 9. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2  
23  
24  
25 samples in fecal immunochemical test screening without affecting attendance. *Clin Gastroenterol*  
26  
27  
28 *Hepatol*. 2011;9(4):333-339.  
29
- 30  
31 10. Cai S-R, Zhu H-H, Huang Y-Q, et al. Cost-effectiveness between double and single fecal  
32  
33  
34 immunochemical test(s) in a mass colorectal cancer screening. *Biomed Res Int*. 2016;2016:6830713.  
35
- 36  
37 11. Moosavi S, Enns R, Gentile L, et al. Comparison of one versus two fecal immunochemical  
38  
39  
40 tests in the detection of colorectal neoplasia in a population-based colorectal cancer screening  
41  
42  
43 program. *Can J Gastroenterol Hepatol*. 2016;2016:5914048.  
44
- 45  
46 12. Wieten E, de Klerk CM, Lansdorp-Vogelaar I, et al. A quarter of participants with advanced  
47  
48  
49 neoplasia have discordant results from 2-sample fecal immunochemical tests for colorectal cancer  
50  
51  
52 screening. *Clin Gastroenterol Hepatol*. 2020;18(8):1805-1811.  
53
- 54  
55 13. Toyoshima O, Hata K, Yoshida S, et al. New-generation chromoendoscopy may increase  
56  
57  
58 confidence in the DISCARD2 study. *Gut*. 2018;67(9):1742-1743.  
59  
60

- 1  
2  
3  
4 14. Toyoshima O, Yoshida S, Nishizawa T, et al. CF290 for pancolonoscopic chromoendoscopy  
5  
6 improved sessile serrated polyp detection and procedure time: a propensity score-matching study.  
7  
8 Endosc Int Open. 2019;7(8):E987-E993.  
9  
10  
11  
12  
13 15. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma  
14  
15 detection during screening colonoscopy. N Engl J Med. 2006;355(24):2533-2541.  
16  
17  
18  
19 16. Toyoshima O, Nishizawa T, Sakitani K, et al. Colonoscopy using back brace support belt: A  
20  
21 randomized, prospective trial. JGH Open. 2020;4(3):441-445.  
22  
23  
24  
25 17. Toyoshima O, Nishizawa T, Yoshida S, et al. Expert endoscopists with high adenoma  
26  
27 detection rates frequently detect diminutive adenomas in proximal colon. Endosc Int Open.  
28  
29 2020;8(6):E775-E782.  
30  
31  
32  
33  
34 18. Brierley JD, Gospodarowicz MK, Wittekind C, eds. UICC TNM classification of malignant  
35  
36 tumours. 8th ed. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.  
37  
38  
39  
40 19. Schlemper R, Riddell R, Kato Y, et al. The Vienna classification of gastrointestinal  
41  
42 epithelial neoplasia. Gut. 2000;47(2):251-255.  
43  
44  
45  
46 20. Ishihara S, Watanabe T, Akahane T, et al. Tumor location is a prognostic factor in poorly  
47  
48 differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the  
49  
50 colon. Int J Colorectal Dis. 2012;27(3):371-379.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 21. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult  
5  
6  
7 blood test and total colonoscopy in the asymptomatic population. *Gastroenterology*.  
8  
9  
10 2005;129(2):422-428.  
11  
12  
13 22. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and  
14  
15  
16 false-negative results from the fecal immunochemical test. *Clin Gastroenterol Hepatol*.  
17  
18  
19 2013;11(7):832-838.  
20  
21  
22 23. Yamaji Y, Majima K, Wada R, et al. Simulating positive predictive values in two-sample  
23  
24  
25 fecal immunochemical test screening. *J Gastrointestinal Cancer Screen*. 2017;55(5):666-675. [in  
26  
27  
28 Japanese with English abstract]. [https://www.jstage.jst.go.jp/article/jsgcs/55/5/55\\_666/\\_pdf/-char/ja](https://www.jstage.jst.go.jp/article/jsgcs/55/5/55_666/_pdf/-char/ja).  
29  
30  
31 24. Loveday C, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in  
32  
33  
34 the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling  
35  
36  
37 study [published online August 29, 2020]. *Gut*.  
38  
39  
40 25. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after  
41  
42  
43 screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal  
44  
45  
46 Cancer. *Gastroenterology*. 2012;143(3):844-857.  
47  
48  
49 26. Wolf AMD, Fonham ETH, Church TR, et al. Colorectal cancer screening for average-risk  
50  
51  
52 adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*.  
53  
54  
55 2018;68(4):250-281.  
56  
57  
58 27. Suspected cancer: recognition and referral. NICE guideline [NG12]: NICE: National  
59  
60

1  
2  
3  
4 Institute for Health and Care Excellence, 2017.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## TABLES

Table 1. Study patients.

|                              | Total          | Positive FIT   |                |                | Other than positive FIT |             |                          |
|------------------------------|----------------|----------------|----------------|----------------|-------------------------|-------------|--------------------------|
|                              |                | Total          | FIT (2+)       | FIT (+)        | Total                   | Symptom     | Screening + surveillance |
| <b>No.</b>                   | 9147           | 1705           | 264            | 1441           | 7442                    | 1826        | 5616                     |
| <b>Age, mean (SD), years</b> | 53.6<br>(12.5) | 50.7<br>(12.3) | 52.7<br>(13.7) | 50.3<br>(12.0) | 54.2<br>(12.4)          | 49.2 (13.4) | 55.8 (11.6)              |
| <b>Male, n (%)</b>           | 4534<br>(49.6) | 797<br>(46.7)  | 144<br>(54.5)  | 653<br>(45.3)  | 3737<br>(50.2)          | 722 (39.5)  | 3015 (53.7)              |

Abbreviation: FIT, faecal immunochemical test. FIT (2+) indicates 2-positive FIT results. FIT (+) indicates positive FIT results other than FIT (2+).

**Table 2. Detection rates of colorectal cancer based on the indication for colonoscopy.**

|   | Total<br>I | Positive FIT      |                    |                   | Other than positive FIT |                   |                             |
|---|------------|-------------------|--------------------|-------------------|-------------------------|-------------------|-----------------------------|
|   |            | Total             | FIT (2+)           | FIT (+)           | Total<br>I              | Sympto<br>m       | Screening +<br>surveillance |
| <b>No.</b>                                    | 9147       | 1705              | 264                | 1441              | 7442                    | 1826              | 5616                        |
| <b>All cancers (including in situ),<br/>n</b> | 87         | 59                | 32                 | 27                | 28                      | 15                | 13                          |
| <b>Detection rate</b>                         | 1.0%       | 3.5% <sup>a</sup> | 12.1% <sup>b</sup> | 1.9% <sup>c</sup> | 0.4%                    | 0.8% <sup>d</sup> | 0.2%                        |
| <b>Invasive cancers, n</b>                    | 41         | 29                | 22                 | 7                 | 12                      | 7                 | 5                           |
| <b>Detection rate</b>                         | 0.4%       | 1.7% <sup>a</sup> | 8.3% <sup>b</sup>  | 0.5%              | 0.2%                    | 0.4% <sup>e</sup> | 0.1%                        |

Abbreviation: FIT, faecal immunochemical test. FIT (2+) indicates 2-positive FIT results. FIT (+) indicates positive FIT results other than FIT (2+).

<sup>a</sup>  $P < .001$ , Positive FIT vs. Other than positive FIT.

<sup>b</sup>  $P < .001$ , FIT (2+) vs. FIT (+).

<sup>c</sup>  $P = .008$ , FIT (+) vs. Symptom.

<sup>d</sup>  $P < .001$ , Symptom vs. Screening + surveillance.

<sup>e</sup>  $P = .01$ , Symptom vs. Screening + surveillance.

**Table 3. Colorectal cancer detection rates based on age and FIT positivity groups.**

|   | Age ≥50 years     |                    |                   | Age <50 years |                    |         |
|---|-------------------|--------------------|-------------------|---------------|--------------------|---------|
|   | Total             | FIT (2+)           | FIT (+)           | Total         | FIT (2+)           | FIT (+) |
| <b>No.</b>                                | 829               | 140                | 689               | 876           | 124                | 752     |
| <b>All cancers (including in situ), n</b> | 42                | 18                 | 24                | 17            | 14                 | 3       |
| <b>Detection rate</b>                     | 5.1% <sup>a</sup> | 12.9% <sup>b</sup> | 3.5% <sup>a</sup> | 1.9%          | 11.3% <sup>b</sup> | 0.4%    |
| <b>Invasive cancers, n</b>                | 19                | 12                 | 7                 | 10            | 10                 | 0       |
| <b>Detection rate</b>                     | 2.3% <sup>a</sup> | 8.6% <sup>b</sup>  | 1.0% <sup>c</sup> | 1.1%          | 8.1% <sup>b</sup>  | 0.0%    |

Abbreviation: FIT, faecal immunochemical test. FIT (2+) indicates 2-positive FIT results. FIT (+) indicates positive FIT results other than FIT (2+).

<sup>a</sup>  $P < .001$ , Age ≥50 years vs. Age <50 years.

<sup>b</sup>  $P < .001$ , FIT (2+) vs. FIT (+).

<sup>c</sup>  $P = .006$ , Age ≥50 years vs. Age <50 years.

**Table 4. Features of colorectal cancers based on indication for colonoscopy.**

|   | Total        | Positive FIT             |                          | Other than positive FIT |                          |
|---|--------------|--------------------------|--------------------------|-------------------------|--------------------------|
|   |              | FIT (2+)                 | FIT (+)                  | Symptom                 | Screening + Surveillance |
| <b>No.</b>  | 87           | 32                       | 27                       | 15                      | 13                       |
| <b>Location (Proximal/Distal), n</b>              | 24/63        | 10/22 <sup>a</sup>       | 6/21 <sup>a</sup>        | 1/14 <sup>a</sup>       | 7/6 <sup>a</sup>         |
| <b>Size (SD), mm</b>                              | 26.5 (21.8)  | 31.2 (22.7) <sup>b</sup> | 21.0 (22.0) <sup>b</sup> | 30.0 (20.4)             | 22.0 (19.8)              |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 46/14/8/16/3 | 10/7/4/10/1 <sup>c</sup> | 20/3/2/1/1 <sup>c</sup>  | 8/1/1/4/1               | 8/3/1/1/0                |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 82/4         | 30/2                     | 27/0                     | 13/1                    | 12/1                     |

Abbreviation: FIT, faecal immunochemical test. FIT (2+) indicates 2-positive FIT results. FIT (+) indicates positive FIT results other than FIT (2+). "Proximal" indicates from the caecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. SD: standard deviation. "T stage" of the tumour was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma. One squamous cell carcinoma was excluded from this analysis.

<sup>a</sup>  $P=.04$ , Amongst indication groups.

<sup>b</sup>  $P=.006$ , FIT (2+) vs. FIT (+).

<sup>c</sup>  $P<.001$ , FIT (2+) vs. FIT (+).

1  
2  
3 **FIGURE LEGEND**  
4  
5

6 **Figure 1. Cancer detection rates stratified by T stages based on age and FIT positivity groups.**

7  
8 T stage was classified according to the UICC TNM Classification.

9  
10 FIT (2+) had a higher percentage of invasive cancers than in FIT (+) in both age groups.

11  
12 Abbreviation: FIT, faecal immunochemical test. FIT (2+) indicates 2-positive FIT results. FIT (+) indicates positive  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
FIT results other than FIT (2+).

For peer review only




Figure 1.

peer review only

**Supplemental Table 1. Details of the FIT (+) groups.**

|   | <b>FIT (2+)</b> | <b>FIT (+/-)</b> | <b>FIT (+/?)</b> |
|---|-----------------|------------------|------------------|
| <b>No.</b>  | 264             | 1018             | 423              |
| <b>Age, mean (SD), years</b>                      | 52.7 (13.7)     | 50.3 (11.9)      | 50.3 (12.3)      |
| <b>Male, n (%)</b>                                | 144 (54.5)      | 469 (46.1)       | 184 (43.5)       |
| <b>All cancers (including in situ), n</b>         | 32              | 19               | 8                |
| <b>Detection rate</b>                             | 12.1%           | 1.9%             | 1.9%             |
| <b>Invasive cancers, n</b>                        | 22              | 3                | 4                |
| <b>Detection rate</b>                             | 8.3%            | 0.3%             | 0.9%             |
| <b>Age ≥50 years</b>                              |                 |                  |                  |
| <b>No.</b>  | 140             | 490              | 199              |
| <b>All cancers (including in situ), n</b>         | 18              | 17               | 7                |
| <b>Detection rate</b>                             | 12.9%           | 3.5%             | 3.5%             |
| <b>Invasive cancers, n</b>                        | 12              | 3                | 4                |
| <b>Detection rate</b>                             | 8.6%            | 0.6%             | 2.0%             |
| <b>Age &lt;50 years</b>                           |                 |                  |                  |
| <b>No.</b>  | 124             | 528              | 224              |
| <b>All cancers (including in situ), n</b>         | 14              | 2                | 1                |
| <b>Detection rate</b>                             | 11.3%           | 0.4%             | 0.4%             |
| <b>Invasive cancers, n</b>                        | 10              | 0                | 0                |
| <b>Detection rate</b>                             | 8.1%            | 0.0%             | 0.0%             |
| <b>Features of cancers</b>                        |                 |                  |                  |
| <b>Location (Proximal/Distal), n</b>              | 10/22           | 5/14             | 1/7              |
| <b>Size (SD), mm</b>                              | 31.2 (22.7)     | 17.4 (9.7)       | 29.6 (37.9)      |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 10/7/4/10/1     | 16/1/2/0/0       | 4/2/0/1/1        |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 30/2            | 19/0             | 8/0              |

Abbreviation: FIT, fecal immunochemical test. FIT (2+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT. FIT (+/?) includes a 1-positive result for the 1-sample FIT and unknown number-positive results for the 2-sample FIT. SD: standard deviation. "Proximal" indicates from the cecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. "T stage" of the tumor was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma.

# BMJ Open

## Priority stratification for colonoscopy based on 2-sample faecal immunochemical test screening: results from a cross-sectional study at an endoscopy clinic in Japan

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2020-046055.R1   |
| Article Type:                   | Original research  |
| Date Submitted by the Author:   | 30-Mar-2021  |
| Complete List of Authors:       | Toyoshima, Osamu; Toyoshima Endoscopy Clinic, Gastroenterology; The University of Tokyo, Department of Gastroenterology<br>Yamaji, Yutaka; Tokyo Pharmaceutical Industry Health Insurance Society, Health Development Center<br>Nishizawa, Toshihiro; Toyoshima Endoscopy Clinic, Gastroenterology; International Medical and Welfare College, Department of Gastroenterology and Hepatology<br>Yoshida, Shuntaro; Toyoshima Endoscopy Clinic, Gastroenterology<br>Yamada, Tomoharu; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kurokawa, Ken; The University of Tokyo, Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Obata, Miho; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kondo, Ryo; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Toba, Masahito; Toba Clinic, Gastroenterology<br>Koike, Kazuhiko; The University of Tokyo, Department of Gastroenterology |
| <b>Primary Subject Heading</b>: | Gastroenterology and hepatology  |
| Secondary Subject Heading:      | Health informatics, Health policy, General practice / Family practice  |
| Keywords:                       | Gastrointestinal tumours < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Gastroenterology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT   |
|                                 |  |

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 1 **ORIGINAL ARTICLE**

5  
6  
7 2  
8  
9  
10 3 **TITLE**

11  
12  
13 4 **Priority stratification for colonoscopy based on 2-sample faecal immunochemical test**  
14  
15  
16 5 **screening: results from a cross-sectional study at an endoscopy clinic in Japan**  
17  
18  
19 6

20  
21  
22 7 **AUTHORS**

23  
24  
25 8 Osamu Toyoshima, MD, PhD<sup>1,2</sup>, Yutaka Yamaji, MD, PhD<sup>3</sup>, Toshihiro Nishizawa, MD, PhD<sup>1,4</sup>,

26  
27  
28 9 Shuntaro Yoshida, MD, PhD<sup>1,2</sup>, Tomoharu Yamada, MD, PhD<sup>1,2</sup>, Ken Kurokawa, MD, PhD<sup>1,2</sup>,

29  
30  
31 10 Miho Obata, MD<sup>1,2</sup>, Ryo Kondo, MD<sup>1,2</sup>, Masahito Toba, MD, PhD<sup>5</sup>, and Kazuhiko Koike, MD,

32  
33  
34 11 PhD<sup>2</sup>  
35  
36  
37 12  
38  
39

40 13 **Affiliations**

41  
42  
43 14 <sup>1</sup> Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo, Japan

44  
45  
46 15 <sup>2</sup> Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo,  
47  
48  
49 16 Japan

50  
51  
52 17 <sup>4</sup> Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo,  
53  
54  
55 18 Japan

56  
57  
58 19 <sup>4</sup> Department of Gastroenterology and Hepatology, International University of Health and Welfare,  
59  
60

1  
2  
3  
4 1 Narita Hospital, Chiba, Japan  
5

6  
7 2 <sup>5</sup> Gastroenterology, Toba Clinic, Tokyo, Japan  
8  
9

10 3  
11  
12

13 4 **Corresponding Author:** Osamu Toyoshima, MD, Ph D, Director, Gastroenterology, Toyoshima  
14

15  
16 5 Endoscopy Clinic.  
17

18  
19 6 6-17-5 Seijo, Setagaya-ku, Tokyo 157-0066, JAPAN  
20  
21

22 7 Email: [t@ichou.com](mailto:t@ichou.com); Phone: +81-3-5429-9555; Fax: +81-3-5429-9511  
23  
24

25 8  
26  
27

28 9 **Contributors:** Study concept and design: OT, YY, and KKo. Acquisition, analysis, or interpretation  
29

30  
31 10 of data: OT, YY, TN, SY, TY, KKu, MO, RK, and MT. Writing of the manuscript: OT. Critical  
32

33  
34 11 revision of the manuscript for important intellectual content: YY, TN, SY, TY, KKu, MO, RK, MT,  
35

36  
37 12 and KKo. Statistical analysis: OT and YY. Supervision: KKo. All authors approved the submitted  
38

39  
40 13 version of the manuscript.  
41  
42

43 14 **Competing interests:** None.  
44  
45

46 15 **Funding:** The authors have not declared a specific grant for this research from any funding agency  
47

48  
49 16 in the public, commercial or not-for-profit sectors.  
50  
51

52 17 **Ethics approval:** [review board] Certificated Review Board, Hattori Clinic (certification no.  
53

54  
55 18 CRB3180027), [approval date] September 6th, 2019, [approval no.] S1909-U06, [registration site]  
56

57  
58 19 UMIN-CTR system ([https://rctportal.niph.go.jp/en/detail?trial\\_id=UMIN000018541](https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000018541)), [registration  
59

1  
2  
3  
4 1 no.] UMIN000018541.  
5  
6

7 2 **Informed consent statement:** Written informed consents were obtained from the participants.  
8  
9

10 3 **Patient and public involvement:** Patients and/or the public were not involved in the design,  
11  
12  
13 4 conduct, report, or dissemination of this research.  
14  
15

16 5 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
17  
18

19 6 **Data availability statement:** Data are available upon reasonable request. Additional data can be  
20  
21  
22 7 obtained by emailing OT at t@ichou.com. All requests for data sharing should be discussed with OT  
23  
24  
25 8 at the first instance.  
26  
27

28 9 **STROBE statement:** The authors have read the STROBE Statement checklist of items, and the  
29  
30  
31 10 manuscript was prepared and revised according to the STROBE Statement checklist of items.  
32  
33

34 11 **Running title:** Triage by 2-sample FIT  
35  
36

37 12 **Manuscript word count:** 3139 words  
38  
39

40 13 **Keywords:** hemocult; colorectal cancer; colorectal cancer screening; colonoscopy; cancer  
41  
42  
43 14 prevention  
44  
45

46 15  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1           2           3 4   1   **ABSTRACT**

5  
6  
7   2   **Objectives** Little has been reported on the yield and characteristics of colorectal neoplasia detected  
8  
9  
10   3   by the 2-sample faecal immunochemical test (FIT), particularly the difference between subjects with  
11  
12  
13   4   2-positive results on the 2-sample FIT and those with 1-positive results. We aimed to assess risk  
14  
15  
16   5   stratification amongst patients with positive 2-sample FIT to prioritise colonoscopy.  
17

18  
19   6   **Design** A retrospective cross-sectional study  
20

21  
22   7   **Setting** A single-centre, representative endoscopy clinic in Japan  
23  
24

25   8   **Participants** Consecutive patients who underwent colonoscopy were enrolled. Indications for  
26  
27  
28   9   colonoscopy included 2-positive results on the 2-sample FIT (FIT (+/+)), 1-positive results on the 2-  
29  
30  
31   10   sample FIT (FIT (+/-)), and other reasons (non-FIT group, including presence of symptoms,  
32  
33  
34   11   screening, or surveillance).  
35  
36

37   12   **Primary and secondary outcome measures** Primary outcomes were detection rates of colorectal  
38  
39  
40   13   cancers, including in situ (all cancers) and invasive cancers, based on the indications for  
41  
42  
43   14   colonoscopy. Secondary outcomes were cancer features, such as location, size, T stage, and  
44  
45  
46   15   histological subtype.  
47  
48

49   16   **Results** Of the 9147 patients, 264 underwent colonoscopy following FIT (+/+), 1018 following FIT  
50  
51  
52   17   (+/-), and 7442 for reasons other than positive FIT. Detection rates of all (and invasive) cancers in  
53  
54  
55   18   the FIT (+/+), FIT (+/-), and non-FIT groups were 12.1% (8.3%), 1.9% (0.3%), and 0.4% (0.2%),  
56  
57  
58   19   respectively. The cancer detection rates were much higher in the FIT (+/+) group than in the FIT  
59  
60

1  
2  
3  
4 1 (+/-) group, which in turn had higher rates than the non-FIT group. Moreover, the FIT (+/+) group  
5  
6  
7 2 showed more advanced T stages on TNM classification (Tis/T1/T2/T3/T4: 10/7/4/10/1) than the FIT  
8  
9  
10 3 (+/-) group (16/1/2/0/0,  $P<.001$ ).

11  
12  
13 4 **Conclusions** Two-positive results for 2-sample FIT showed a much higher yield for more advanced  
14  
15  
16 5 colorectal cancers than the 1-positive result. High priority for diagnostic colonoscopy should be  
17  
18  
19 6 assigned to patients with 2-positive-FIT results.

20  
21  
22 7  
23  
24  
25 8 (278 words)

26  
27  
28 9  
29  
30 10 **Strengths and limitations of this study**

- 31  
32  
33 11 ● This study shows real-world data on 2-sample FIT in Japan, where 2-sample FIT-based  
34  
35  
36 12 colorectal screening has been conducted for many years throughout the country.
- 37  
38  
39 13 ● This study investigated detection rates and features of colorectal cancers in patients with 1- and  
40  
41  
42 14 2-positive results for the 2-sample FIT.
- 43  
44  
45  
46 15 ● This study also evaluated colorectal cancers in patients aged <50 years with 2-positive results for  
47  
48  
49 16 the 2-sample FIT.
- 50  
51  
52 17 ● The retrospective cross-sectional design at a single endoscopy clinic was a limitation.
- 53  
54  
55 18 ● We could not assess the FIT kit brand, faecal haemoglobin concentration, or patients' symptoms  
56  
57  
58 19 in detail.

## 1 INTRODUCTION

Colorectal cancer is one of the leading cancers worldwide, with 1.8 million new cases and 860,000 deaths annually, and has a significant impact on public health.<sup>1</sup> Screening for colorectal cancer has shown significant effects on reducing the morbidity and mortality, and is also economical.<sup>2</sup> There are several options for colorectal cancer screening, such as primary colonoscopy, sigmoidoscopy, and stool-based tests.<sup>2</sup> Amongst stool-based tests, the faecal immunochemical test (FIT) is now widely used instead of the guaiac faecal occult blood test, because of its higher accuracy and ease of handling.<sup>3,4</sup> Although its accuracy is limited compared to that of primary colonoscopy, FIT is noninvasive and can conserve the resources required for colonoscopy and reduce human contact. Hence, FIT might facilitate the safety and prioritisation of patients during the COVID-19 pandemic.<sup>5</sup>

In Japan, the population-based annual 2-sample FIT has been used for colorectal cancer screening for three decades since 1992.<sup>6</sup> For implementation and effectiveness, the number of FIT samples required, the interval between two FITs, and the FIT brands have been estimated.<sup>4</sup> The 2-sample method has been reported to have the best sensitivity and specificity for colorectal cancer.<sup>3,7</sup> Some investigators also reported that the sensitivity for advanced neoplasia was higher by using the 2-sample method than by the 1-sample method.<sup>8,9</sup>

At least 1-positive result is defined as a positive result in the 2-sample FIT method.<sup>3,7-9</sup> Few studies have investigated the yield and characteristics of neoplasia detected by 2-sample FIT.<sup>8-10</sup> In particular, little is known about the differences between the subjects with 2-positive results in the 2-

1  
2  
3  
4 1 sample FIT and those with 1-positive result.<sup>11,12</sup> In this study, we investigated the detection rates and  
5  
6  
7 2 features of invasive and in situ colorectal cancers detected by colonoscopy at our institution based on  
8  
9  
10 3 the indication for colonoscopy, focussing on the positivity patterns in the 2-sample FIT.  
11  
12  
13 4

## 16 5 **METHODS**

### 19 6 **Study design**

22 7 This cross-sectional study included consecutive patients who underwent colonoscopy at the  
23  
24  
25 8 Toyoshima Endoscopy Clinic from April 2017 to August 2019. The indications for colonoscopy  
26  
27  
28 9 included a positive FIT result, evaluation of symptoms, screening, surveillance, and treatment.  
29  
30

31 10 Samples for FIT measurements were collected from two consecutive bowel movements. FITs were  
32  
33  
34 11 conducted at our clinic or at referral medical institutions. The FIT kits included both qualitative and  
35  
36  
37 12 quantitative types. The FIT kit brand and cutoff values for positivity were chosen by the institutes  
38  
39  
40 13 conducting the FIT. At our institute, FIT was performed using OC-Auto Sampling Bottle 3 (Eiken  
41  
42  
43 14 Chemical Co., Ltd., Tokyo, Japan) with the threshold of 32 µg haemoglobin/g faeces. We divided the  
44  
45  
46 15 patients who were FIT positive into two categories: FIT (+/+) and FIT (+/-). We defined 2-positive  
47  
48  
49 16 results for 2 samples as FIT (+/+) and 1-positive result for 2 samples as FIT (+/-). Patients with a 1-  
50  
51  
52 17 positive result for the 1-sample FIT and positive FIT results with unknown number of positivity were  
53  
54  
55 18 excluded from this study; these findings are summarised in **Supplementary Table 1**. The symptoms  
56  
57  
58 19 included abnormal bowel habits, haematochezia, and abdominal pain. The surveillance included  
59  
60



1  
2  
3  
4 1 patients with a medical history of colorectal cancer, colorectal polyps, or inflammatory bowel  
5  
6  
7 2 diseases. Treatment involved polypectomy and haemostasis. We excluded colonoscopies performed  
8  
9  
10 3 for treatment from this study. All indications other than positive FIT were divided into two  
11  
12  
13 4 categories: symptoms and screening + surveillance (asymptomatic).  
14  
15  
16 5

## 19 6 **Ethics**

22 7 This study was conducted in accordance with ethical guidelines for medical studies in Japan.  
23  
24  
25 8 Written informed consent was obtained from patients at the time of colonoscopy to use their data for  
26  
27  
28 9 research purposes. The study design was described in a protocol prepared by Toyoshima Endoscopy  
29  
30  
31 10 Clinic and was approved by the Certificated Review Board, Hattori Clinic on 6 September 2019  
32  
33  
34 11 (approval no. S1909-U06, registration no. UMIN000018541). We published this study's protocol on  
35  
36  
37 12 our institute's website (<http://www.ichou.com>), so that patients can opt out of the study. All clinical  
38  
39  
40 13 investigations were conducted according to the ethical guidelines of the Declaration of Helsinki.  
41  
42  
43 14

## 46 15 **Colonoscopy**

49 16 Colonoscopies were performed by certified gastroenterologists. Olympus Elite 290 endoscope  
50  
51  
52 17 series (Olympus, Tokyo, Japan) was used.<sup>13,14</sup> The clinical data were recorded on an electronic  
53  
54  
55 18 endoscopy reporting system, T-File System (STS Medic, Tokyo, Japan). The data included the  
56  
57  
58 19 patients' baseline characteristics (age, sex, and indication for colonoscopy) and tumour  
59  
60

1  
2  
3  
4 1 characteristics (location and size).  
5  
6

7 2 All colonoscopists were instructed to observe the entire colorectum, with a withdrawal time of 6  
8  
9  
10 3 minutes or longer.<sup>15,16</sup> Polyps 15 mm in size or smaller were resected at the time of the examination,  
11  
12  
13 4 and if the polyp was larger than 15 mm, or if invasive cancer was suspected, the patient was referred  
14  
15  
16 5 to the hospital.<sup>17</sup>  
17  
18  
19 6

## 22 7 **Colorectal cancer**

23  
24  
25 8 Colorectal cancer was treated by endoscopic resection, surgery, chemotherapy, and/or best  
26  
27  
28 9 supportive care. The patients received treatment at our clinic or at the hospital they were referred to.  
29  
30

31 10 Colorectal cancer was diagnosed by histopathology. The location of cancer was determined by  
32  
33  
34 11 colonoscopy, surgery, or CT. The location from the caecum to the transverse colon was defined as  
35  
36  
37 12 proximal colon. The size of the cancer was measured by colonoscopy, pathology, or CT. The extent  
38  
39  
40 13 of tumour invasion was determined by pathology in combination with colonoscopy and CT findings.  
41  
42

43 14 Tumours were classified according to the T stage of the UICC TNM classification.<sup>18</sup> We included  
44  
45  
46 15 noninvasive carcinoma (carcinoma in situ) as a cancer.<sup>19</sup> The histological subtype of the cancer was  
47  
48  
49 16 determined by histopathological evaluation of the resected or biopsy specimens. Four histological  
50  
51  
52 17 subtypes of adenocarcinomas (i.e., well-differentiated, moderately-differentiated, poorly-  
53  
54  
55 18 differentiated, and mucinous adenocarcinoma) were classified into two categories: well- +  
56  
57  
58 19 moderately-differentiated and poorly-differentiated + mucinous adenocarcinoma based on the  
59  
60

1  
2  
3  
4 1 prognosis of the subtypes.<sup>20</sup>  
5  
6  
7 2  
8  
9

### 10 3 **Outcomes**

11  
12  
13 4 The main outcomes were detection rates of all colorectal cancers (including carcinomas in situ) and  
14  
15  
16 5 those of invasive colorectal cancers, based on the indication for colonoscopy. The secondary  
17  
18  
19 6 outcomes were the features of the cancers, such as location, size, T stage, and histological subtype.  
20  
21  
22 7 We also divided the patients into 2 groups according to age: <50 years and  $\geq$ 50 years, and analysed  
23  
24  
25 8 the detection rates and features of the cancers.  
26  
27  
28 9

### 31 10 **Statistical analysis**

32  
33  
34 11 The detection rates were compared using the chi-squared test or Fisher's exact test. The  
35  
36  
37 12 characteristics of the cancer were compared using the Mann-Whitney U test, chi-squared test, or  
38  
39  
40 13 Fisher's exact test. The association between the T stages of colorectal cancers and the number of  
41  
42  
43 14 positive results of FIT was analysed using Spearman's rank correlation test. A two-sided *P* value  
44  
45  
46 15 <.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS  
47  
48  
49 16 version 21.0 (IBM SPSS, Armonk, NY).  
50  
51  
52 17  
53  
54

### 55 18 **Patient and public involvement**

56  
57  
58 19 Patients and/or the public were not involved in the design, or conduct, or report, or dissemination  
59  
60

1  
2  
3  
4 1 plans of this research.  
5  
6  
7 2  
8  
9

### 10 3 **RESULTS**

#### 13 4 **Characteristics of the study patients**

16 5 During the study period, 9321 patients underwent colonoscopy. Of them, we excluded 174 patients  
17  
18  
19 6 for undergoing colonoscopy for treatment, 136 patients for a 1-positive result for the 1-sample FIT,  
20  
21  
22 7 and 287 patients for positive FIT results with unknown number of positivity. Finally, 8724 patients  
23  
24  
25 8 (age, mean  $\pm$  SD: 53.7  $\pm$  12.5 years; male sex: 49.9%) were eligible for this study. In all, 1282  
26  
27  
28 9 colonoscopies were performed following positive FIT results. Of the positive FIT results, 264 were  
29  
30  
31 10 FIT (++) and 1018 were FIT (+/-). The remaining 7442 colonoscopies performed for indications  
32  
33  
34 11 other than positive FIT included 1826 for evaluation of the symptoms, and 5616 for screening (2394)  
35  
36  
37 12 + surveillance (3222), all these were performed without FIT investigation (**Table 1**).  
38  
39  
40 13

#### 43 14 **Cancer detection rates based on the indication for colonoscopy**

46 15 The detection rates of colorectal cancer based on the indication for colonoscopy are shown in  
47  
48  
49 16 **Table 2**. All colorectal cancers (including carcinoma in situ) and invasive cancers were detected in  
50  
51  
52 17 0.9% (79/8724 cases) and 0.4% (37 cases) of patients included in the study. The detection rates of all  
53  
54  
55 18 cancers and invasive cancers in FIT-positive patients were 4.0% (51/1282 cases) and 2.0% (25  
56  
57  
58 19 cases), which were significantly higher than those detected patients who did not undergo FIT (0.4%  
59  
60

1  
2  
3  
4 1 for all cancers, 28/7442,  $P<.001$ ; 0.2% for invasive cancers, 12 cases,  $P<.001$ ).

5  
6  
7 2 Amongst FIT-positive patients, the detection rate of all cancers in the FIT (+/+) group was very  
8  
9  
10 3 high at 12.1% (32/264 patients) and that in the FIT (+/-) group was 1.9% (19/1018 patients). Invasive  
11  
12  
13 4 cancers accounted for 8.3% (22 cases) in the FIT (+/+) group and 0.3% (3 cases) in the FIT (+/-)  
14  
15  
16 5 group. FIT (+/+) had significantly higher detection rates than FIT (+/-) ( $P<.001$  and  $P<.001$ ,  
17  
18  
19 6 respectively).

20  
21  
22 7 Amongst patients who did not undergo FIT, the cancer detection rates in symptomatic patients  
23  
24  
25 8 were significantly higher than in asymptomatic patients, in whom colonoscopy was performed for  
26  
27  
28 9 screening and surveillance (0.8% and 0.2% for all cancers,  $P<.001$ ; 0.4% and 0.1% for invasive  
29  
30  
31 10 cancers,  $P=.01$ ).

32  
33  
34 11 Additionally, the rate of cancer detection was significantly higher in patients with FIT (+/-) than in  
35  
36  
37 12 those with symptoms (1.9% and 0.8%,  $P=.02$ , respectively).

38  
39  
40 13 The detection rate of benign adenomas was significantly higher in the FIT (+/+) group than in the  
41  
42  
43 14 FIT (+/-) group (61.4% vs. 47.7%,  $P<.001$ ). The difference in the detection rates of adenomas  
44  
45  
46 15 between the FIT (+/+) group and the FIT (+/-) group was less remarkable than those of cancers.  
47  
48

49 16  
50  
51  
52 17 **Cancer detection rates based on age and FIT positivity groups**

53  
54  
55 18 **Table 3** shows the rates of detection for colorectal cancer based on age group and FIT positivity  
56  
57  
58 19 patterns.

1  
2  
3  
4 1 In patients aged  $\geq 50$  years, the FIT (+/+) group showed the highest rate of cancer detection (12.9%  
5  
6  
7 2 for all cancers and 8.6% for invasive cancers). For the FIT (+/-) group, the respective rates were  
8  
9  
10 3 3.5% and 0.6%, which were significantly lower than those in the FIT (+/+) group ( $P < .001$  and  
11  
12  
13 4  $P < .001$ ), suggesting that early stage cancers are more predominant.

14  
15  
16 5 In the  $< 50$  years age group as well, the rate of cancer detection was higher in the FIT (+/+) group  
17  
18  
19 6 (11.3% for all cancers and 8.1% for invasive cancers). They were comparable to those in the  $\geq 50$   
20  
21  
22 7 age group. However, the detection rate in the FIT (+/-) group was low (0.4% for all cancers and 0.0%  
23  
24  
25 8 for invasive cancers, respectively); moreover, the detection rate for all cancers was lower than that in  
26  
27  
28 9 the same FIT (+/-) group at age  $\geq 50$  years ( $P < .001$ ).

### 10 11 **The features of the colorectal cancers**

12 **Table 4** shows the features of colorectal cancers based on the indication for colonoscopy. The  
13  
14 colorectal cancers in patients with FIT (+/+) were larger than those in the FIT (+/-) patients (31.2  
15  
16 mm and 17.4 mm,  $P = .004$ ). The T stage of FIT (+/+) colorectal cancer was more advanced than that  
17  
18 of the FIT (+/-) cancers ( $P < .001$ ). Although cancers were generally likely to be located in the distal  
19  
20 colon or rectum, the cancers detected during screening and surveillance colonoscopies were  
21  
22 predominantly in the proximal colon (proximal colon/distal colon and rectum: 7/6 for screening and  
23  
24 surveillance vs. 16/50 for the others,  $P = .046$ ).

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3  
4 1 positivity patterns (FIT [+/+] and FIT [+/-]) are shown in **Figure 1**. FIT (+/+) patients had  
5  
6  
7 2 predominantly more advanced cancers than the FIT (+/-) patients (Tis/T1/T2/T3/T4 for FIT [+/+] vs.  
8  
9  
10 3 FIT [+/-]: 6/2/3/7/0 vs. 14/1/2/0/0 in  $\geq 50$  years:  $P < .001$ ; 4/5/1/3/1 vs. 2/0/0/0/0 in  $< 50$  years:  
11  
12  
13 4  $P = .10$ ).

### 6 **Patients with positive FIT overlapping symptoms or history of colorectal lesions**

7 Because FIT was conducted annually as part of colorectal cancer screening system, independent of  
8 symptoms or history of colorectal lesions, the FIT groups included patients with accompanying  
9 symptoms or history of polypectomy. In the positive FIT groups, 31 patients were symptomatic and  
10 19 had a history of colorectal lesions. In situ cancers were found in three patients with 2-positive FIT  
11 results and haematochezia. No cancer was detected in patients with positive FIT results and history  
12 of colorectal lesions.

### 14 **DISCUSSION**

15 This study found that cases with 2-positive FIT results in 2 samples had significantly high rates of  
16 more advanced-stage colorectal cancers amongst all cases with positive FIT results. Although FIT  
17 has been an important screening tool for colorectal cancer and can help in selecting candidates for  
18 diagnostic colonoscopy, patients with 2-positive results were shown to be at the highest risk for life-  
19 threatening cancer. In the face of the COVID-19 pandemic, when resources for colonoscopy are

1  
2  
3  
4 1 limited, FIT can stratify the patients' risk. The study outcomes indicate that those with FIT (2+)  
5  
6  
7 2 should be given the highest priority for colonoscopy.  
8  
9

10 3 Although the sensitivity of FIT is superior to that of the guaiac test,<sup>3,4,21,22</sup> it decreases  
11  
12  
13 4 considerably for early-stage cancer or high-grade dysplasia compared with direct colonoscopy.  
14  
15  
16 5 Morikawa *et al.*<sup>23</sup> compared the results of 1-sample FIT and total colonoscopy in asymptomatic  
17  
18  
19 6 Japanese patients and reported that the sensitivity for invasive cancer was 78.3% (18/23) for Dukes'  
20  
21  
22 7 stages C or D, 70.0% (7/10) for Dukes' stage B, and 52.8% (19/36) for Dukes' stage A, and that for  
23  
24  
25 8 high-grade dysplasia was 32.7% (39/119). A similar study from Taiwan reported that the 1-sample  
26  
27  
28 9 FIT showed a sensitivity of 100% (5/5) for cancers in T2-4 stages and 66.7% (12/18) for those of Tis  
29  
30  
31 10 or T1.<sup>24</sup> The 2-sample method was adopted to improve the sensitivity of FIT.<sup>3,7-9</sup>  
32  
33

34 11 A simulation analysis based on the results of colonoscopic screening in the Japanese subjects  
35  
36  
37 12 predicted markedly higher positive predictive values (PPVs) for invasive cancers in patients with 2  
38  
39  
40 13 positive-FIT results.<sup>25</sup> The PPVs were estimated to be 1.7% and 26% for male subjects in their 50s  
41  
42  
43 14 with 1 and 2 positive FITs, respectively. PPVs could increase because of lower rates of false  
44  
45  
46 15 positivity in cases with 2 positive FITs. The effect of improving the sensitivity could be higher for  
47  
48  
49 16 early stage lesions than for advanced cancers, for which the sensitivity is already high in single-  
50  
51  
52 17 sample FIT. One positive result in two samples was predicted to detect predominantly earlier-stage  
53  
54  
55 18 lesions. Few investigators have reported the actual findings of colonoscopy comparing one and two  
56  
57  
58 19 positive FITs in 2-sample FIT screening. Our result is compatible with a previous Canadian study,  
59  
60



1  
2  
3  
4 1 which reported PPVs for colorectal cancer to be 1% and 8%, in patients with 1 and 2 positive FITs,  
5  
6  
7 2 respectively.<sup>11</sup> A recent study from the Netherlands suggested that 2-positive FITs from two samples  
8  
9  
10 3 of the same bowel movement also have high cancer detection rates.<sup>12</sup> The present study showed more  
11  
12  
13 4 advanced stages of colorectal cancers were predominant in patients with 2-positive FITs.

16 5 The FIT (+/-) group showed higher rates of cancer detection than those in whom the colonoscopy  
17  
18  
19 6 was performed for evaluation of symptoms, screening, or surveillance. This might be partly because  
20  
21  
22 7 the patients' symptoms at our clinic were generally mild. Although further evaluations are necessary,  
23  
24  
25 8 FIT might be helpful in making decisions about performing colonoscopy in symptomatic patients<sup>26</sup>  
26  
27  
28 9 or at the time of surveillance for patients after polypectomy.<sup>27</sup>

31 10 Even in patients <50 years of age, those with FIT (++) showed negligible rates of colorectal  
32  
33  
34 11 cancers, and in those with FIT (+/-), the rates were very low. Our results suggest that patients under  
35  
36  
37 12 50 years of age with 2 positive FITs might need to receive a higher priority for colonoscopy than  
38  
39  
40 13 those over 50 years with 1 positive FIT. There is some discussion as to whether colorectal cancer  
41  
42  
43 14 screening should be started for subjects under 50 years of age, in whom the incidence of colorectal  
44  
45  
46 15 cancer is quite low but is increasing.<sup>28</sup> If they were screened by 2-positive results from 2-sample  
47  
48  
49 16 FITs, the cost-benefit balance might be acceptable.

52 17 The present study cannot answer whether the 2-sample FIT is superior to the 1-sample quantitative  
53  
54  
55 18 FIT as a tool for organised colorectal cancer screening program. The 1-sample FIT is simpler and  
56  
57  
58 19 less expensive at the primary screening step. Careful and wide-range evaluations are necessary to

1  
2  
3  
4 1 select the best method, which should depend on the various conditions of the population. An  
5  
6  
7 2 advantage of the 2-sample FIT is based on the considerable discordance in FIT results between  
8  
9  
10 3 samples collected even from the same person. The result can sometimes change from 1 ng/mL to  
11  
12  
13 4 1000 ng/mL (cutoff: 100 ng/mL = 20 µg Hb/g faeces) by the next day. The 2-sample FIT may have  
14  
15  
16 5 advantages over the 1-sample FIT, even after adjusting the threshold, under some circumstances. On  
17  
18  
19 6 the other hand, for risk stratification, the appropriate secondary cutoff values for the 1-sample  
20  
21  
22 7 quantitative FIT need to be decided for each FIT kit. The 2-sample FIT, using the established  
23  
24  
25 8 threshold for each FIT kit, has two possible results: 2-positive or 1-positive result.

26  
27  
28 9 We propose that patients with 2-positive results should be prioritised for colonoscopy, especially  
29  
30  
31 10 when resources are limited. In addition, given the COVID-19 pandemic, patients are likely to  
32  
33  
34 11 hesitate to undergo colonoscopy. In such cases, they should be strongly encouraged to receive  
35  
36  
37 12 colonoscopy with high priority. It may be useful to stratify patients with symptoms in a primary care  
38  
39  
40 13 setting. In the setting of 1-sample FIT screening, our results suggest that secondary FIT administered  
41  
42  
43 14 to patients with a positive primary FIT result can help identify patients at higher risk for whom  
44  
45  
46 15 colonoscopy should not be delayed.

## 16 17 **Limitations and Strengths**

18 This study has several limitations. First, it was conducted at a single endoscopy unit; hence, the  
19 results cannot be generalised. However, the indications and quality of colonoscopy as well as the

1  
2  
3  
4 1 criteria for diagnosis were well controlled. Two-sample FIT-based colorectal screening has been  
5  
6  
7 2 conducted for many years throughout Japan. Our results could well represent the regular practice of  
8  
9  
10 3 colorectal screening in Japan. Second, the FIT kit brands and cutoff values for positivity were  
11  
12  
13 4 various and unknown in many cases that were referred from other medical institutions for  
14  
15  
16 5 colonoscopy. The guidelines for colorectal cancer screening in Japan only recommend the 2-sample  
17  
18  
19 6 FIT as standard, with no specific kits or cutoff values. As differences in FIT kit features and  
20  
21  
22 7 thresholds have been known to affect screening performance,<sup>29</sup> these variations are certainly a  
23  
24  
25 8 limitation of our study. However, a notable difference in the results between 2-positive and 1-  
26  
27  
28 9 positive FIT groups shown in our study suggests a common trend irrespective of kits brand. Third,  
29  
30  
31 10 we did not assess the patients' symptoms in detail, as cancer detection rates were low in symptomatic  
32  
33  
34 11 patients without FIT evaluation. However, the symptoms in our patients were generally mild. In  
35  
36  
37 12 populations with more serious symptoms, they could also be useful to urge early colonoscopy.<sup>30</sup>  
38  
39  
40 13 Fourth, positive predictive values are highly associated with the expected prevalence of lesions in the  
41  
42  
43 14 study population. Our results are susceptible to bias due to heterogeneity among our patients, which  
44  
45  
46 15 is a limitation of our study design. However, based on our results, detection rates of more advanced  
47  
48  
49 16 tumours were excellent in patients with 2-positive results, whereas they were generally quite low in  
50  
51  
52 17 the other positive groups. Further, this trend was observed irrespective of age groups. Although the  
53  
54  
55 18 results could change according to the study population, we assume that higher risk for advanced-  
56  
57  
58 19 stage lesions in 2-positive FIT results is generally true for various populations.  
59  
60

1  
2  
3  
4 1  
5  
6  
7 2 In conclusion, 2-positive results for 2 samples of FIT showed a much higher yield of advanced  
8  
9  
10 3 colorectal cancers than the 1-positive result, which also showed a higher yield than colonoscopy  
11  
12  
13 4 performed in patients with symptoms or with an associated history. The highest priority for  
14  
15  
16 5 diagnostic colonoscopy should be assigned to patients with 2-positive-FIT results.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
2. Segnan N, Patnick J, von Karsa L, eds. *European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis.* 1st ed. Luxembourg: Publications Office of the European Union; 2010.
3. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. *Am J Gastroenterol.* 2010;105(9):2017-2025.
4. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal Immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology.* 2017;152(5):1217-1237.
5. Issaka RB, Somsouk M. Colorectal Cancer Screening and Prevention in the COVID-19 Era [published online May 13, 2020]. *JAMA Health Forum.*
6. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut.* 2015;64(10):1637-1649.

- 1  
2  
3  
4 7. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical  
5  
6  
7 fecal occult blood test for detection of colorectal neoplasia. *Hepatogastroenterology*.  
8  
9  
10 1999;46(25):228-231.  
11
- 12  
13 8. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of  
14  
15  
16 samples and positivity cutoff. What is the best strategy for colorectal cancer screening? *Br J Cancer*.  
17  
18  
19 2009;100(2):259-265.  
20
- 21  
22 9. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2  
23  
24  
25 samples in fecal immunochemical test screening without affecting attendance. *Clin Gastroenterol*  
26  
27  
28 *Hepatol*. 2011;9(4):333-339.  
29
- 30  
31 10. Cai S-R, Zhu H-H, Huang Y-Q, et al. Cost-effectiveness between double and single fecal  
32  
33  
34 immunochemical test(s) in a mass colorectal cancer screening. *Biomed Res Int*. 2016;2016:6830713.  
35
- 36  
37 11. Moosavi S, Enns R, Gentile L, et al. Comparison of one versus two fecal immunochemical  
38  
39  
40 tests in the detection of colorectal neoplasia in a population-based colorectal cancer screening  
41  
42  
43 program. *Can J Gastroenterol Hepatol*. 2016;2016:5914048.  
44
- 45  
46 12. Wieten E, de Klerk CM, Lansdorp-Vogelaar I, et al. A quarter of participants with advanced  
47  
48  
49 neoplasia have discordant results from 2-sample fecal immunochemical tests for colorectal cancer  
50  
51  
52 screening. *Clin Gastroenterol Hepatol*. 2020;18(8):1805-1811.  
53
- 54  
55 13. Toyoshima O, Hata K, Yoshida S, et al. New-generation chromoendoscopy may increase  
56  
57  
58 confidence in the DISCARD2 study. *Gut*. 2018;67(9):1742-1743.  
59  
60

- 1  
2  
3  
4 14. Toyoshima O, Yoshida S, Nishizawa T, et al. CF290 for pancolonoscopic chromoendoscopy  
5  
6  
7 improved sessile serrated polyp detection and procedure time: a propensity score-matching study.  
8  
9  
10 Endosc Int Open. 2019;7(8):E987-E993.  
11  
12  
13 15. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma  
14  
15  
16 detection during screening colonoscopy. *N Engl J Med*. 2006;355(24):2533-2541.  
17  
18  
19 16. Toyoshima O, Nishizawa T, Sakitani K, et al. Colonoscopy using back brace support belt: A  
20  
21  
22 randomized, prospective trial. *JGH Open*. 2020;4(3):441-445.  
23  
24  
25 17. Toyoshima O, Nishizawa T, Yoshida S, et al. Expert endoscopists with high adenoma  
26  
27  
28 detection rates frequently detect diminutive adenomas in proximal colon. *Endosc Int Open*.  
29  
30  
31 2020;8(6):E775-E782.  
32  
33  
34 18. Brierley JD, Gospodarowicz MK, Wittekind C, eds. UICC TNM classification of malignant  
35  
36  
37 tumours. 8th ed. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.  
38  
39  
40 19. Schlemper R, Riddell R, Kato Y, et al. The Vienna classification of gastrointestinal  
41  
42  
43 epithelial neoplasia. *Gut*. 2000;47(2):251-255.  
44  
45  
46 20. Ishihara S, Watanabe T, Akahane T, et al. Tumor location is a prognostic factor in poorly  
47  
48  
49 differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the  
50  
51  
52 colon. *Int J Colorectal Dis*. 2012;27(3):371-379.  
53  
54  
55 21. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of bowel  
56  
57  
58 cancer screening with a faecal immunochemical test: results from a pilot study within the national  
59  
60

1  
2  
3  
4 screening programme in England. *Gut* 2017;66(9):1631-44.

5  
6  
7 22. Clark G, Strachan JA, Carey FA, et al. Transition to quantitative faecal immunochemical  
8  
9  
10 testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel  
11  
12  
13 screening programme. *Gut* 2021;70(1):106-13.

14  
15  
16 23. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult  
17  
18  
19 blood test and total colonoscopy in the asymptomatic population. *Gastroenterology*.  
20  
21  
22 2005;129(2):422-428.

23  
24  
25 24. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and  
26  
27  
28 false-negative results from the fecal immunochemical test. *Clin Gastroenterol Hepatol*.  
29  
30  
31 2013;11(7):832-838.

32  
33  
34 25. Yamaji Y, Majima K, Wada R, et al. Simulating positive predictive values in two-sample  
35  
36  
37 fecal immunochemical test screening. *J Gastrointestinal Cancer Screen*. 2017;55(5):666-675. [in  
38  
39  
40 Japanese with English abstract]. [https://www.jstage.jst.go.jp/article/jsgcs/55/5/55\\_666/\\_pdf/-char/ja](https://www.jstage.jst.go.jp/article/jsgcs/55/5/55_666/_pdf/-char/ja).

41  
42  
43 26. Loveday C, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in  
44  
45  
46 the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling  
47  
48  
49 study [published online August 29, 2020]. *Gut*.

50  
51  
52 27. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after  
53  
54  
55 screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal  
56  
57  
58 Cancer. *Gastroenterology*. 2012;143(3):844-857.



- 1  
2  
3  
4 28. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk  
5  
6  
7 adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*.  
8  
9  
10 2018;68(4):250-281.  
11  
12  
13 29. Chapman CJ, Banerjea A, Humes DJ, et al. Choice of faecal immunochemical test matters:  
14  
15  
16 comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal  
17  
18  
19 cancer. *Clin Chem Lab Med* 2020;cclm-2020-1170.  
20  
21  
22 30. Suspected cancer: recognition and referral. NICE guideline [NG12]: NICE: National  
23  
24  
25 Institute for Health and Care Excellence, 2017.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TABLES

Table 1. Study patients.

|                              | Total          | Positive FIT   |                |                | Other than positive FIT |                |                          |
|------------------------------|----------------|----------------|----------------|----------------|-------------------------|----------------|--------------------------|
|                              |                | Total          | FIT (+/+)      | FIT (+/-)      | Total                   | Symptom        | Screening + surveillance |
| <b>No.</b>                   | 8724           | 1282           | 264            | 1018           | 7442                    | 1826           | 5616                     |
| <b>Age, mean (SD), years</b> | 53.7<br>(12.5) | 50.8<br>(12.4) | 52.7<br>(13.7) | 50.3<br>(12.0) | 54.2<br>(12.4)          | 49.2<br>(13.4) | 55.8 (11.6)              |
| <b>Male, n (%)</b>           | 4350<br>(49.9) | 613<br>(47.8)  | 144<br>(54.5)  | 653<br>(45.3)  | 3737<br>(50.2)          | 722<br>(39.5)  | 3015 (53.7)              |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

**Table 2. Detection rates of colorectal cancer based on the indication for colonoscopy.**

|   | Total | Positive FIT      |                    |                   | Other than positive FIT |                   |                          |
|---|-------|-------------------|--------------------|-------------------|-------------------------|-------------------|--------------------------|
|   |       | Total             | FIT (+/+)          | FIT (+/-)         | Total                   | Symptom           | Screening + surveillance |
| <b>No.</b>                                | 8724  | 1282              | 264                | 1018              | 7442                    | 1826              | 5616                     |
| <b>All cancers (including in situ), n</b> | 79    | 51                | 32                 | 19                | 28                      | 15                | 13                       |
| <b>Detection rate</b>                     | 0.9%  | 4.0% <sup>a</sup> | 12.1% <sup>b</sup> | 1.9% <sup>c</sup> | 0.4%                    | 0.8% <sup>d</sup> | 0.2%                     |
| <b>Invasive cancers, n</b>                | 37    | 25                | 22                 | 3                 | 12                      | 7                 | 5                        |
| <b>Detection rate</b>                     | 0.4%  | 2.0% <sup>a</sup> | 8.3% <sup>b</sup>  | 0.3%              | 0.2%                    | 0.4% <sup>e</sup> | 0.1%                     |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

<sup>a</sup>  $P < .001$ , Positive FIT vs. Other than positive FIT.

<sup>b</sup>  $P < .001$ , FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P = .02$ , FIT (+/-) vs. Symptom.

<sup>d</sup>  $P < .001$ , Symptom vs. Screening + surveillance.

<sup>e</sup>  $P = .01$ , Symptom vs. Screening + surveillance.

**Table 3. Colorectal cancer detection rates based on age and FIT positivity groups.**

|   | Age ≥50 years     |                    |                   | Age <50 years |                    |           |
|---|-------------------|--------------------|-------------------|---------------|--------------------|-----------|
|   | Total             | FIT (+/+)          | FIT (+/-)         | Total         | FIT (+/+)          | FIT (+/-) |
| <b>No.</b>                                | 630               | 140                | 490               | 652           | 124                | 528       |
| <b>All cancers (including in situ), n</b> | 35                | 18                 | 17                | 16            | 14                 | 2         |
| <b>Detection rate</b>                     | 5.6% <sup>a</sup> | 12.9% <sup>b</sup> | 3.5% <sup>c</sup> | 2.5%          | 11.3% <sup>b</sup> | 0.4%      |
| <b>Invasive cancers, n</b>                | 15                | 12                 | 3                 | 10            | 10                 | 0         |
| <b>Detection rate</b>                     | 2.4%              | 8.6% <sup>b</sup>  | 0.6%              | 1.5%          | 8.1% <sup>b</sup>  | 0%        |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

<sup>a</sup>  $P=0.006$ , Age ≥50 years vs. Age <50 years.

<sup>b</sup>  $P<0.001$ , FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P<0.001$ , Age ≥50 years vs. Age <50 years.

**Table 4. Features of colorectal cancers based on indication for colonoscopy.**

|   | Total        | Positive FIT             |            | Other than positive FIT |                          |
|---|--------------|--------------------------|------------|-------------------------|--------------------------|
|   |              | FIT (+/+)                | FIT (+/-)  | Symptom                 | Screening + Surveillance |
| <b>No.</b>  | 79           | 32                       | 19         | 15                      | 13                       |
| <b>Location (Proximal/Distal), n</b>              | 23/56        | 10/22                    | 5/14       | 1/14                    | 7/6 <sup>a</sup>         |
| <b>Size (SD), mm</b>                              | 26.1 (19.9)  | 31.2 (22.7) <sup>b</sup> | 17.4 (9.7) | 30.0 (20.4)             | 22.0 (19.8)              |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 42/12/8/15/2 | 10/7/4/10/1 <sup>c</sup> | 16/1/2/0/0 | 8/1/1/4/1               | 8/3/1/1/0                |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 74/4         | 30/2                     | 19/0       | 13/1                    | 12/1                     |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT. "Proximal" indicates from the caecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. SD: standard deviation. "T stage" of the tumour was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma. One squamous cell carcinoma was excluded from this analysis.

<sup>a</sup>  $P=.046$ , Screening + Surveillance vs. the others.

<sup>b</sup>  $P=.004$ , FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P<.001$ , FIT (+/+) vs. FIT (+/-).

## FIGURE LEGEND



### **Figure 1. Cancer detection rates stratified by T stages based on age and FIT positivity groups.**

T stage was classified according to the UICC TNM Classification.

FIT (+/+) had a higher percentage of invasive cancers than in FIT (+/-).

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

For peer review only



**Supplementary Table 1. Details of the positive FIT groups**

|   | FIT (+/+)   | FIT (+/-)               | FIT (+)           | FIT (+/?)         |
|---|-------------|-------------------------|-------------------|-------------------|
| <b>No.</b>  | 264         | 1018                    | 136               | 287               |
| <b>Age, mean (SD), years</b>                      | 52.7 (13.7) | 50.3 (11.9)             | 48.3 (12.1)       | 51.2 (12.2)       |
| <b>Male, n (%)</b>                                | 144 (54.5)  | 469 (46.1)              | 65 (47.8)         | 119 (41.5)        |
| <b>All cancers (including in situ), n</b>         | 32          | 19                      | 2                 | 6                 |
| <b>Detection rate</b>                             | 12.1%       | 1.9% <sup>a</sup>       | 1.5% <sup>a</sup> | 2.1% <sup>a</sup> |
| <b>Invasive cancers, n</b>                        | 22          | 3                       | 0                 | 4                 |
| <b>Detection rate</b>                             | 8.3%        | 0.3% <sup>a</sup>       | 0.0% <sup>a</sup> | 1.4% <sup>a</sup> |
| <b>Age ≥50 years</b>                              |             |                         |                   |                   |
| <b>No.</b>  | 140         | 490                     | 54                | 145               |
| <b>All cancers (including in situ), n</b>         | 18          | 17                      | 2                 | 5                 |
| <b>Detection rate</b>                             | 12.9%       | 3.5% <sup>a</sup>       | 3.7%              | 3.4% <sup>b</sup> |
| <b>Invasive cancers, n</b>                        | 12          | 3                       | 0                 | 4                 |
| <b>Detection rate</b>                             | 8.6%        | 0.6% <sup>a</sup>       | 0.0% <sup>c</sup> | 2.8% <sup>c</sup> |
| <b>Age &lt;50 years</b>                           |             |                         |                   |                   |
| <b>No.</b>  | 124         | 528                     | 82                | 142               |
| <b>All cancers (including in situ), n</b>         | 14          | 2                       | 0                 | 1                 |
| <b>Detection rate</b>                             | 11.3%       | 0.4% <sup>a</sup>       | 0.0% <sup>b</sup> | 0.7% <sup>a</sup> |
| <b>Invasive cancers, n</b>                        | 10          | 0                       | 0                 | 0                 |
| <b>Detection rate</b>                             | 8.1%        | 0.0% <sup>a</sup>       | 0.0% <sup>c</sup> | 0.0% <sup>b</sup> |
| <b>Features of cancers</b>                        |             |                         |                   |                   |
| <b>Location (Proximal/Distal), n</b>              | 10/22       | 5/14                    | 1/1               | 0/6               |
| <b>Size (SD), mm</b>                              | 31.2 (22.7) | 17.4 <sup>b</sup> (9.7) | 9.0 (8.5)         | 36.5 (42.0)       |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 10/7/4/10/1 | 16/1/2/0/0              | 2/0/0/0/0         | 2/2/0/1/1         |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 30/2        | 19/0                    | 2/0               | 6/0               |

Abbreviation: FIT, fecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT. FIT (+) indicates a 1-positive result for the 1-sample FIT. FIT (+/?) indicates positive FIT results with unknown number of positivity. SD: standard deviation. "Proximal" indicates from the cecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. "T stage" of the tumor was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma.

<sup>a</sup>  $P < .001$ , vs. FIT (+/+).

<sup>b</sup>  $P < .01$ , vs. FIT (+/+).

<sup>c</sup>  $P < .05$ , vs. FIT (+/+).



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

| Section/Topic             | Item # | Recommendation   | Reported on page #                      |
|---------------------------|--------|--|---|
| Title and abstract        | 1      | (a) Indicate the study’s design with a commonly used term in the title or the abstract   | P1 line3-5, P4 line6-7                  |
|                           |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | P4 line6-P5 line6                       |
| <b>Introduction</b>       |        |  |   |
| Background/rationale      | 2      | Explain the scientific background and rationale for the investigation being reported   | P6 line2-16                             |
| Objectives                | 3      | State specific objectives, including any prespecified hypotheses   | P6 line17-P7 line3                      |
| <b>Methods</b>            |        |  |   |
| Study design              | 4      | Present key elements of study design early in the paper  | P7 line6-P8 line4                       |
| Setting                   | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | P7 line7-8                              |
| Participants              | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants  | P7 line7-P8 line4                       |
| Variables                 | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | P10 line2-7                             |
| Data sources/ measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | P7 line10-P8 line4, P8 line15-P9 line19 |
| Bias                      | 9      | Describe any efforts to address potential sources of bias  | P7 line16-18, P10 line6-7               |
| Study size                | 10     | Explain how the study size was arrived at  | P7 line7-9                              |
| Quantitative variables    | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | P9 line10-19                            |
| Statistical methods       | 12     | (a) Describe all statistical methods, including those used to control for confounding  | P10 line10-15                           |
|                           |        | (b) Describe any methods used to examine subgroups and interactions  | P10 line6-7, 10-15                      |
|                           |        | (c) Explain how missing data were addressed  | N.A.                                    |
|                           |        | (d) If applicable, describe analytical methods taking account of sampling strategy   | N.A.                                    |
|                           |        | (e) Describe any sensitivity analyses  | N.A.                                    |
| <b>Results</b>            |        |  |   |

|                          |     |  |                                    |
|--------------------------|-----|--|------------------------------------|
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | P11 line3-11                       |
|                          |     | (b) Give reasons for non-participation at each stage   | P11 line4-6                        |
|                          |     | (c) Consider use of a flow diagram   | N.A.                               |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | P11 line6-11                       |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | N.A.                               |
| Outcome data             | 15* | Report numbers of outcome events or summary measures   | P11 line14-19                      |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | P12 line1-9                        |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | N.A.                               |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | N.A.                               |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | P12 line16-P13 line8, P14 line4-10 |
| <b>Discussion</b>        |     |  |                                    |
| Key results              | 18  | Summarise key results with reference to study objectives   | P14 line13-19                      |
| Limitations              | 19  | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   | P17 line16-P18 line18              |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | P19 line1-4                        |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | P17 line16-P18 line18              |
| <b>Other information</b> |     |  |                                    |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | P2 line14-15                       |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Priority stratification for colonoscopy based on 2-sample faecal immunochemical test screening: results from a cross-sectional study at an endoscopy clinic in Japan

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2020-046055.R2   |
| Article Type:                   | Original research  |
| Date Submitted by the Author:   | 20-Apr-2021  |
| Complete List of Authors:       | Toyoshima, Osamu; Toyoshima Endoscopy Clinic, Gastroenterology; The University of Tokyo, Department of Gastroenterology<br>Yamaji, Yutaka; Tokyo Pharmaceutical Industry Health Insurance Society, Health Development Center<br>Nishizawa, Toshihiro; Toyoshima Endoscopy Clinic, Gastroenterology; International Medical and Welfare College, Department of Gastroenterology and Hepatology<br>Yoshida, Shuntaro; Toyoshima Endoscopy Clinic, Gastroenterology<br>Yamada, Tomoharu; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kurokawa, Ken; The University of Tokyo, Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Obata, Miho; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Kondo, Ryo; The University of Tokyo, Department of Gastroenterology; Toyoshima Endoscopy Clinic, Gastroenterology<br>Toba, Masahito; Toba Clinic, Gastroenterology<br>Koike, Kazuhiko; The University of Tokyo, Department of Gastroenterology |
| <b>Primary Subject Heading</b>: | Gastroenterology and hepatology  |
| Secondary Subject Heading:      | Health informatics, Health policy, General practice / Family practice  |
| Keywords:                       | Gastrointestinal tumours < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Gastroenterology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT   |
|                                 |  |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 1 **ORIGINAL ARTICLE**

5  
6  
7 2  
8  
9  
10 3 **TITLE**

11  
12  
13 4 **Priority stratification for colonoscopy based on 2-sample faecal immunochemical test**  
14  
15  
16 5 **screening: results from a cross-sectional study at an endoscopy clinic in Japan**  
17  
18  
19 6

20  
21  
22 7 **AUTHORS**

23  
24  
25 8 Osamu Toyoshima, MD, PhD<sup>1,2</sup>, Yutaka Yamaji, MD, PhD<sup>3</sup>, Toshihiro Nishizawa, MD, PhD<sup>1,4</sup>,

26  
27  
28 9 Shuntaro Yoshida, MD, PhD<sup>1,2</sup>, Tomoharu Yamada, MD, PhD<sup>1,2</sup>, Ken Kurokawa, MD, PhD<sup>1,2</sup>,

29  
30  
31 10 Miho Obata, MD<sup>1,2</sup>, Ryo Kondo, MD<sup>1,2</sup>, Masahito Toba, MD, PhD<sup>5</sup>, and Kazuhiko Koike, MD,

32  
33  
34 11 PhD<sup>2</sup>  
35  
36  
37 12  
38  
39

40 13 **Affiliations**

41  
42  
43 14 <sup>1</sup> Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo, Japan

44  
45  
46 15 <sup>2</sup> Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo,  
47  
48  
49 16 Japan

50  
51  
52 17 <sup>4</sup> Health Development Center, Tokyo Pharmaceutical Industry Health Insurance Society, Tokyo,  
53  
54  
55 18 Japan

56  
57  
58 19 <sup>4</sup> Department of Gastroenterology and Hepatology, International University of Health and Welfare,  
59  
60

1  
2  
3  
4 1 Narita Hospital, Chiba, Japan  
5

6  
7 2 <sup>5</sup> Gastroenterology, Toba Clinic, Tokyo, Japan  
8  
9

10 3  
11  
12

13 4 **Corresponding Author:** Osamu Toyoshima, MD, Ph D, Director, Gastroenterology, Toyoshima  
14

15  
16 5 Endoscopy Clinic.  
17

18  
19 6 6-17-5 Seijo, Setagaya-ku, Tokyo 157-0066, JAPAN  
20  
21

22 7 Email: [t@ichou.com](mailto:t@ichou.com); Phone: +81-3-5429-9555; Fax: +81-3-5429-9511  
23  
24

25 8  
26  
27

28 9 **Contributors:** Study concept and design: OT, YY, and KKo. Acquisition, analysis, or interpretation  
29

30  
31 10 of data: OT, YY, TN, SY, TY, KKu, MO, RK, and MT. Writing of the manuscript: OT. Critical  
32

33  
34 11 revision of the manuscript for important intellectual content: YY, TN, SY, TY, KKu, MO, RK, MT,  
35

36  
37 12 and KKo. Statistical analysis: OT and YY. Supervision: KKo. All authors approved the submitted  
38

39  
40 13 version of the manuscript.  
41  
42

43 14 **Competing interests:** None.  
44  
45

46 15 **Funding:** The authors have not declared a specific grant for this research from any funding agency  
47

48  
49 16 in the public, commercial or not-for-profit sectors.  
50  
51

52 17 **Ethics approval:** [review board] Certificated Review Board, Hattori Clinic (certification no.  
53

54  
55 18 CRB3180027), [approval date] September 6th, 2019, [approval no.] S1909-U06, [registration site]  
56

57  
58 19 UMIN-CTR system ([https://rctportal.niph.go.jp/en/detail?trial\\_id=UMIN000018541](https://rctportal.niph.go.jp/en/detail?trial_id=UMIN000018541)), [registration  
59

1  
2  
3  
4 1 no.] UMIN000018541.  
5  
6

7 2 **Informed consent statement:** Written informed consents were obtained from the participants.  
8  
9

10 3 **Patient and public involvement:** Patients and/or the public were not involved in the design,  
11  
12  
13 4 conduct, report, or dissemination of this research.  
14  
15

16 5 **Provenance and peer review:** Not commissioned; externally peer reviewed.  
17  
18

19 6 **Data availability statement:** Data are available upon reasonable request. Additional data can be  
20  
21  
22 7 obtained by emailing OT at t@ichou.com. All requests for data sharing should be discussed with OT  
23  
24  
25 8 at the first instance.  
26  
27

28 9 **STROBE statement:** The authors have read the STROBE Statement checklist of items, and the  
29  
30  
31 10 manuscript was prepared and revised according to the STROBE Statement checklist of items.  
32  
33

34 11 **Running title:** Triage by 2-sample FIT  
35  
36

37 12 **Manuscript word count:** 3165 words  
38  
39

40 13 **Keywords:** hemocult; colorectal cancer; colorectal cancer screening; colonoscopy; cancer  
41  
42  
43 14 prevention  
44  
45

46 15  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 **ABSTRACT**

2  
3  
4  
5  
6  
7 2 **Objectives** Little has been reported on the yield and characteristics of colorectal neoplasia detected  
8  
9  
10 3 by the 2-sample faecal immunochemical test (FIT), particularly the difference between subjects with  
11  
12  
13 4 2-positive results on the 2-sample FIT and those with 1-positive results. We aimed to assess risk  
14  
15  
16 5 stratification amongst patients with positive 2-sample FIT to prioritise colonoscopy.  
17

18  
19 6 **Design** A retrospective cross-sectional study  
20

21  
22 7 **Setting** A single-centre, representative endoscopy clinic in Japan  
23  
24

25 8 **Participants** Consecutive patients who underwent colonoscopy were enrolled. Indications for  
26  
27  
28 9 colonoscopy included 2-positive results on the 2-sample FIT (FIT (+/+)), 1-positive results on the  
29  
30  
31 10 2-sample FIT (FIT (+/-)), and other reasons (non-FIT group, including presence of symptoms,  
32  
33  
34 11 screening, or surveillance).  
35  
36

37 12 **Primary and secondary outcome measures** Primary outcomes were detection rates of colorectal  
38  
39  
40 13 cancers, including in situ (all cancers) and invasive cancers, based on the indications for  
41  
42  
43 14 colonoscopy. Secondary outcomes were cancer features, such as location, size, T stage, and  
44  
45  
46 15 histological subtype.  
47  
48

49 16 **Results** Of the 9147 patients, 264 underwent colonoscopy following FIT (+/+), 1018 following FIT  
50  
51  
52 17 (+/-), and 7442 for reasons other than positive FIT. Detection rates of all (and invasive) cancers in  
53  
54  
55 18 the FIT (+/+), FIT (+/-), and non-FIT groups were 12.1% (8.3%), 1.9% (0.3%), and 0.4% (0.2%),  
56  
57  
58 19 respectively. The cancer detection rates were much higher in the FIT (+/+) group than in the FIT  
59  
60



1  
2  
3  
4 1 (+/-) group, which in turn had higher rates than the non-FIT group. Moreover, the FIT (+/+) group  
5  
6  
7 2 showed more advanced T stages on TNM classification (Tis/T1/T2/T3/T4: 10/7/4/10/1) than the FIT  
8  
9  
10 3 (+/-) group (16/1/2/0/0,  $P<.001$ ).

11  
12  
13 4 **Conclusions** Two-positive results for 2-sample FIT showed a much higher yield for more advanced  
14  
15  
16 5 colorectal cancers than the 1-positive result. High priority for diagnostic colonoscopy should be  
17  
18  
19 6 assigned to patients with 2-positive-FIT results.

20  
21  
22 7  
23  
24  
25 8 (278 words)

26  
27  
28 9  
29  
30 10 **Strengths and limitations of this study**

- 31  
32  
33 11 ● This study shows real-world data on 2-sample FIT in Japan, where 2-sample FIT-based  
34  
35  
36 12 colorectal screening has been conducted for many years throughout the country.
- 37  
38  
39 13 ● This study investigated detection rates and features of colorectal cancers in patients with 1- and  
40  
41  
42 14 2-positive results for the 2-sample FIT.
- 43  
44  
45  
46 15 ● This study also evaluated colorectal cancers in patients aged <50 years with 2-positive results for  
47  
48  
49 16 the 2-sample FIT.
- 50  
51  
52 17 ● The retrospective cross-sectional design at a single endoscopy clinic was a limitation.
- 53  
54  
55 18 ● We could not assess the FIT kit brand, faecal haemoglobin concentration, or patients' symptoms  
56  
57  
58 19 in detail.

## 1 INTRODUCTION

Colorectal cancer is one of the leading cancers worldwide, with 1.8 million new cases and 860,000 deaths annually, and has a significant impact on public health.<sup>1</sup> Screening for colorectal cancer has shown significant effects on reducing the morbidity and mortality, and is also economical.<sup>2</sup> There are several options for colorectal cancer screening, such as primary colonoscopy, sigmoidoscopy, and stool-based tests.<sup>2</sup> Amongst stool-based tests, the faecal immunochemical test (FIT) is now widely used instead of the guaiac faecal occult blood test, because of its higher accuracy and ease of handling.<sup>3,4</sup> Although its accuracy is limited compared to that of primary colonoscopy, FIT is noninvasive and can conserve the resources required for colonoscopy and reduce human contact. Hence, FIT might facilitate the safety and prioritisation of patients during the COVID-19 pandemic.<sup>5</sup>

In Japan, the population-based annual 2-sample FIT has been used for colorectal cancer screening for three decades since 1992.<sup>6</sup> For implementation and effectiveness, the number of FIT samples required, the interval between two FITs, and the FIT brands have been estimated.<sup>4</sup> The 2-sample method has been reported to have the best sensitivity and specificity for colorectal cancer.<sup>3,7</sup> Some investigators also reported that the sensitivity for advanced neoplasia was higher by using the 2-sample method than by the 1-sample method.<sup>8,9</sup>

At least 1-positive result is defined as a positive result in the 2-sample FIT method.<sup>3,7-9</sup> Few studies have investigated the yield and characteristics of neoplasia detected by 2-sample FIT.<sup>8-10</sup> In particular, little is known about the differences between the subjects with 2-positive results in the

1  
2  
3  
4 1 2-sample FIT and those with 1-positive result.<sup>11,12</sup> In this study, we investigated the detection rates  
5  
6  
7 2 and features of invasive and in situ colorectal cancers detected by colonoscopy at our institution  
8  
9  
10 3 based on the indication for colonoscopy, focussing on the positivity patterns in the 2-sample FIT.  
11  
12

## 13 4 14 15 16 5 **METHODS**

### 17 18 19 6 **Study design**

20  
21  
22 7 This cross-sectional study included consecutive patients who underwent colonoscopy at the  
23  
24  
25 8 Toyoshima Endoscopy Clinic from April 2017 to August 2019. The indications for colonoscopy  
26  
27  
28 9 included a positive FIT result, evaluation of symptoms, screening, surveillance, and treatment.

29  
30  
31 10 Samples for FIT measurements were collected from two consecutive bowel movements. FITs were  
32  
33  
34 11 conducted at our clinic or at referral medical institutions. The FIT kits included both qualitative and  
35  
36  
37 12 quantitative types. The FIT kit brand and cutoff values for positivity were chosen by the institutes  
38  
39  
40 13 conducting the FIT. At our institute, FIT was performed using OC-Auto Sampling Bottle 3 (Eiken  
41  
42  
43 14 Chemical Co., Ltd., Tokyo, Japan) with the threshold of 32 µg haemoglobin/g faeces. We divided the  
44  
45  
46 15 patients who were FIT positive into two categories: FIT (+/+) and FIT (+/-). We defined 2-positive  
47  
48  
49 16 results for 2 samples as FIT (+/+) and 1-positive result for 2 samples as FIT (+/-). Patients with a  
50  
51  
52 17 1-positive result for the 1-sample FIT and positive FIT results with unknown number of positivity  
53  
54  
55 18 were excluded from this study; these findings are summarised in **Supplementary Table 1**. The  
56  
57  
58 19 symptoms included abnormal bowel habits, haematochezia, and abdominal pain. The surveillance  
59  
60

1  
2  
3  
4 1 included patients with a medical history of colorectal cancer, colorectal polyps, or inflammatory  
5  
6  
7 2 bowel diseases. Treatment involved polypectomy and haemostasis. We excluded colonoscopies  
8  
9  
10 3 performed for treatment from this study. All indications other than positive FIT were divided into  
11  
12  
13 4 two categories: symptoms and screening + surveillance (asymptomatic).  
14  
15  
16 5

## 6 **Ethics**

7 This study was conducted in accordance with ethical guidelines for medical studies in Japan.

8 Written informed consent was obtained from patients at the time of colonoscopy to use their data for  
9  
10 research purposes. The study design was described in a protocol prepared by Toyoshima Endoscopy  
11  
12 Clinic and was approved by the Certificated Review Board, Hattori Clinic on 6 September 2019  
13  
14 (approval no. S1909-U06, registration no. UMIN000018541). We published this study's protocol on  
15  
16 our institute's website (<http://www.ichou.com>), so that patients can opt out of the study. All clinical  
17  
18 investigations were conducted according to the ethical guidelines of the Declaration of Helsinki.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

## 46 **Colonoscopy**

47  
48  
49 16 Colonoscopies were performed by certified gastroenterologists. Olympus Elite 290 endoscope  
50  
51  
52 17 series (Olympus, Tokyo, Japan) was used.<sup>13,14</sup> The clinical data were recorded on an electronic  
53  
54  
55 18 endoscopy reporting system, T-File System (STS Medic, Tokyo, Japan). The data included the  
56  
57  
58 19 patients' baseline characteristics (age, sex, and indication for colonoscopy) and tumour  
59  
60

1  
2  
3  
4 1 characteristics (location and size).  
5  
6

7 2 All colonoscopists were instructed to observe the entire colorectum, with a withdrawal time of 6  
8  
9  
10 3 minutes or longer.<sup>15,16</sup> Polyps 15 mm in size or smaller were resected at the time of the examination,  
11  
12  
13 4 and if the polyp was larger than 15 mm, or if invasive cancer was suspected, the patient was referred  
14  
15  
16 5 to the hospital.<sup>17</sup>  
17  
18

## 19 6 20 21 22 7 **Colorectal cancer** 23 24

25 8 Colorectal cancer was treated by endoscopic resection, surgery, chemotherapy, and/or best  
26  
27  
28 9 supportive care. The patients received treatment at our clinic or at the hospital they were referred to.  
29  
30

31 10 Colorectal cancer was diagnosed by histopathology. The location of cancer was determined by  
32  
33  
34 11 colonoscopy, surgery, or CT. The location from the caecum to the transverse colon was defined as  
35  
36  
37 12 proximal colon. The size of the cancer was measured by colonoscopy, pathology, or CT. The extent  
38  
39  
40 13 of tumour invasion was determined by pathology in combination with colonoscopy and CT findings.  
41  
42

43 14 Tumours were classified according to the T stage of the UICC TNM classification.<sup>18</sup> We included  
44  
45  
46 15 noninvasive carcinoma (carcinoma in situ) as a cancer.<sup>19</sup> The histological subtype of the cancer was  
47  
48  
49 16 determined by histopathological evaluation of the resected or biopsy specimens. Four histological  
50  
51  
52 17 subtypes of adenocarcinomas (i.e., well-differentiated, moderately-differentiated,  
53  
54  
55 18 poorly-differentiated, and mucinous adenocarcinoma) were classified into two categories: well- +  
56  
57  
58 19 moderately-differentiated and poorly-differentiated + mucinous adenocarcinoma based on the  
59  
60

1  
2  
3  
4 1 prognosis of the subtypes.<sup>20</sup>  
5  
6  
7 2  
8  
9

### 10 3 **Outcomes**

11  
12  
13 4 The main outcomes were detection rates of all colorectal cancers (including carcinomas in situ) and  
14  
15  
16 5 those of invasive colorectal cancers, based on the indication for colonoscopy. The secondary  
17  
18  
19 6 outcomes were the features of the cancers, such as location, size, T stage, and histological subtype.  
20  
21  
22 7 We also divided the patients into 2 groups according to age: <50 years and  $\geq$ 50 years, and analysed  
23  
24  
25 8 the detection rates and features of the cancers.  
26  
27  
28 9

### 31 10 **Statistical analysis**

32  
33  
34 11 The detection rates were compared using the chi-squared test or Fisher's exact test. The  
35  
36  
37 12 characteristics of the cancer were compared using the Mann-Whitney U test, chi-squared test, or  
38  
39  
40 13 Fisher's exact test. The association between the T stages of colorectal cancers and the number of  
41  
42  
43 14 positive results of FIT was analysed using Spearman's rank correlation test. A two-sided *P* value  
44  
45  
46 15 <.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS  
47  
48  
49 16 version 21.0 (IBM SPSS, Armonk, NY).  
50  
51  
52 17  
53  
54

### 55 18 **Patient and public involvement**

56  
57  
58 19 Patients and/or the public were not involved in the design, or conduct, or report, or dissemination  
59  
60

1  
2  
3  
4 1 plans of this research.  
5  
6  
7 2  
8  
9

### 10 3 **RESULTS**

#### 13 4 **Characteristics of the study patients**

16 5 During the study period, 9321 patients underwent colonoscopy. Of them, we excluded 174 patients  
17  
18  
19 6 for undergoing colonoscopy for treatment, 136 patients for a 1-positive result for the 1-sample FIT,  
20  
21  
22 7 and 287 patients for positive FIT results with unknown number of positivity. Finally, 8724 patients  
23  
24  
25 8 (age, mean  $\pm$  SD: 53.7  $\pm$  12.5 years; male sex: 49.9%) were eligible for this study. In all, 1282  
26  
27  
28 9 colonoscopies were performed following positive FIT results. Of the positive FIT results, 264 were  
29  
30  
31 10 FIT (++) and 1018 were FIT (+/-). The remaining 7442 colonoscopies performed for indications  
32  
33  
34 11 other than positive FIT included 1826 for evaluation of the symptoms, and 5616 for screening (2394)  
35  
36  
37 12 + surveillance (3222), all these were performed without FIT investigation (**Table 1**).  
38  
39  
40 13

#### 43 14 **Cancer detection rates based on the indication for colonoscopy**

46 15 The detection rates of colorectal cancer based on the indication for colonoscopy are shown in  
47  
48  
49 16 **Table 2**. All colorectal cancers (including carcinoma in situ) and invasive cancers were detected in  
50  
51  
52 17 0.9% (79/8724 cases) and 0.4% (37 cases) of patients included in the study. The detection rates of all  
53  
54  
55 18 cancers and invasive cancers in FIT-positive patients were 4.0% (51/1282 cases) and 2.0% (25  
56  
57  
58 19 cases), which were significantly higher than those detected patients who did not undergo FIT (0.4%  
59  
60

1  
2  
3  
4 1 for all cancers, 28/7442,  $P<.001$ ; 0.2% for invasive cancers, 12 cases,  $P<.001$ ).

5  
6  
7 2 Amongst FIT-positive patients, the detection rate of all cancers in the FIT (+/+) group was very  
8  
9  
10 3 high at 12.1% (32/264 patients) and that in the FIT (+/-) group was 1.9% (19/1018 patients). Invasive  
11  
12  
13 4 cancers accounted for 8.3% (22 cases) in the FIT (+/+) group and 0.3% (3 cases) in the FIT (+/-)  
14  
15  
16 5 group. FIT (+/+) had significantly higher detection rates than FIT (+/-) ( $P<.001$  and  $P<.001$ ,  
17  
18  
19 6 respectively).

20  
21  
22 7 Amongst patients who did not undergo FIT, the cancer detection rates in symptomatic patients  
23  
24  
25 8 were significantly higher than in asymptomatic patients, in whom colonoscopy was performed for  
26  
27  
28 9 screening and surveillance (0.8% and 0.2% for all cancers,  $P<.001$ ; 0.4% and 0.1% for invasive  
29  
30  
31 10 cancers,  $P=.01$ ).

32  
33  
34 11 Additionally, the rate of cancer detection was significantly higher in patients with FIT (+/-) than in  
35  
36  
37 12 those with symptoms (1.9% and 0.8%,  $P=.02$ , respectively).

38  
39  
40 13 The detection rate of benign adenomas was significantly higher in the FIT (+/+) group than in the  
41  
42  
43 14 FIT (+/-) group (61.4% vs. 47.7%,  $P<.001$ ). The difference in the detection rates of adenomas  
44  
45  
46 15 between the FIT (+/+) group and the FIT (+/-) group was less remarkable than those of cancers.  
47  
48

49 16  
50  
51  
52 17 **Cancer detection rates based on age and FIT positivity groups**

53  
54  
55 18 **Table 3** shows the rates of detection for colorectal cancer based on age group and FIT positivity  
56  
57  
58 19 patterns.



1  
2  
3  
4 1 In patients aged  $\geq 50$  years, the FIT (+/+) group showed the highest rate of cancer detection (12.9%  
5  
6  
7 2 for all cancers and 8.6% for invasive cancers). For the FIT (+/-) group, the respective rates were  
8  
9  
10 3 3.5% and 0.6%, which were significantly lower than those in the FIT (+/+) group ( $P < .001$  and  
11  
12  
13 4  $P < .001$ ), suggesting that early stage cancers are more predominant.

14  
15  
16 5 In the  $< 50$  years age group as well, the rate of cancer detection was higher in the FIT (+/+) group  
17  
18  
19 6 (11.3% for all cancers and 8.1% for invasive cancers). They were comparable to those in the  $\geq 50$   
20  
21  
22 7 age group. However, the detection rate in the FIT (+/-) group was low (0.4% for all cancers and 0.0%  
23  
24  
25 8 for invasive cancers, respectively); moreover, the detection rate for all cancers was lower than that in  
26  
27  
28 9 the same FIT (+/-) group at age  $\geq 50$  years ( $P < .001$ ).

### 10 11 **The features of the colorectal cancers**

12 **Table 4** shows the features of colorectal cancers based on the indication for colonoscopy. The  
13 colorectal cancers in patients with FIT (+/+) were larger than those in the FIT (+/-) patients (31.2  
14 mm and 17.4 mm,  $P = .004$ ). The T stage of FIT (+/+) colorectal cancer was more advanced than that  
15 of the FIT (+/-) cancers ( $P < .001$ ). Although cancers were generally likely to be located in the distal  
16 colon or rectum, the cancers detected during screening and surveillance colonoscopies were  
17 predominantly in the proximal colon (proximal colon/distal colon and rectum: 7/6 for screening and  
18 surveillance vs. 16/50 for the others,  $P = .046$ ).

19 The cancer detection rates stratified by T stage based on age ( $\geq 50$  and  $< 50$  years) and FIT

1  
2  
3  
4 1 positivity patterns (FIT [+/+] and FIT [+/-]) are shown in **Figure 1**. FIT (+/+) patients had  
5  
6  
7 2 predominantly more advanced cancers than the FIT (+/-) patients (Tis/T1/T2/T3/T4 for FIT [+/+] vs.  
8  
9  
10 3 FIT [+/-]: 6/2/3/7/0 vs. 14/1/2/0/0 in  $\geq 50$  years:  $P < .001$ ; 4/5/1/3/1 vs. 2/0/0/0/0 in  $< 50$  years:  $P = .10$ ).

#### 4 5 **Patients with positive FIT overlapping symptoms or history of colorectal lesions**

6 Because FIT was conducted annually as part of colorectal cancer screening system, independent of  
7 symptoms or history of colorectal lesions, the FIT groups included patients with accompanying  
8 symptoms or history of polypectomy. In the positive FIT groups, 31 patients were symptomatic and  
9 19 had a history of colorectal lesions. In situ cancers were found in three patients with 2-positive FIT  
10 results and haematochezia. No cancer was detected in patients with positive FIT results and history  
11 of colorectal lesions.

#### 13 **DISCUSSION**

14 This study found that cases with 2-positive FIT results in 2 samples had significantly high rates of  
15 more advanced-stage colorectal cancers amongst all cases with positive FIT results. Although FIT  
16 has been an important screening tool for colorectal cancer and can help in selecting candidates for  
17 diagnostic colonoscopy, patients with 2-positive results were shown to be at the highest risk for  
18 life-threatening cancer. In the face of the COVID-19 pandemic, when resources for colonoscopy are

1  
2  
3  
4 1 limited, FIT can stratify the patients' risk. The study outcomes indicate that those with FIT (2+)  
5  
6  
7 2 should be given the highest priority for colonoscopy.  
8  
9

10 3 Although the sensitivity of FIT is superior to that of the guaiac test,<sup>3,4,21,22</sup> it decreases  
11  
12  
13 4 considerably for early-stage cancer or high-grade dysplasia compared with direct colonoscopy.  
14  
15  
16 5 Morikawa *et al.*<sup>23</sup> compared the results of 1-sample FIT and total colonoscopy in asymptomatic  
17  
18  
19 6 Japanese patients and reported that the sensitivity for invasive cancer was 78.3% (18/23) for Dukes'  
20  
21  
22 7 stages C or D, 70.0% (7/10) for Dukes' stage B, and 52.8% (19/36) for Dukes' stage A, and that for  
23  
24  
25 8 high-grade dysplasia was 32.7% (39/119). A similar study from Taiwan reported that the 1-sample  
26  
27  
28 9 FIT showed a sensitivity of 100% (5/5) for cancers in T2-4 stages and 66.7% (12/18) for those of Tis  
29  
30  
31 10 or T1.<sup>24</sup> The 2-sample method was adopted to improve the sensitivity of FIT.<sup>3,7-9</sup>  
32  
33

34 11 A simulation analysis based on the results of colonoscopic screening in the Japanese subjects  
35  
36  
37 12 predicted markedly higher positive predictive values (PPVs) for invasive cancers in patients with 2  
38  
39  
40 13 positive-FIT results.<sup>25</sup> The PPVs were estimated to be 1.7% and 26% for male subjects in their 50s  
41  
42  
43 14 with 1 and 2 positive FITs, respectively. PPVs could increase because of lower rates of false  
44  
45  
46 15 positivity in cases with 2 positive FITs. The effect of improving the sensitivity could be higher for  
47  
48  
49 16 early stage lesions than for advanced cancers, for which the sensitivity is already high in  
50  
51  
52 17 single-sample FIT. One positive result in two samples was predicted to detect predominantly  
53  
54  
55 18 earlier-stage lesions. Few investigators have reported the actual findings of colonoscopy comparing  
56  
57  
58 19 one and two positive FITs in 2-sample FIT screening. Our result is compatible with a previous  
59  
60

1  
2  
3  
4 1 Canadian study, which reported PPVs for colorectal cancer to be 1% and 8%, in patients with 1 and 2  
5  
6  
7 2 positive FITs, respectively.<sup>11</sup> A recent study from the Netherlands suggested that 2-positive FITs  
8  
9  
10 3 from two samples of the same bowel movement also have high cancer detection rates.<sup>12</sup> The present  
11  
12  
13 4 study showed more advanced stages of colorectal cancers were predominant in patients with  
14  
15  
16 5 2-positive FITs.

17  
18  
19 6 The FIT (+/-) group showed higher rates of cancer detection than those in whom the colonoscopy  
20  
21  
22 7 was performed for evaluation of symptoms, screening, or surveillance. This might be partly because  
23  
24  
25 8 the patients' symptoms at our clinic were generally mild. Although further evaluations are necessary,  
26  
27  
28 9 FIT might be helpful in making decisions about performing colonoscopy in symptomatic patients<sup>26</sup>  
29  
30  
31 10 or at the time of surveillance for patients after polypectomy.<sup>27</sup>

32  
33  
34 11 Even in patients <50 years of age, those with FIT (++) showed negligible rates of colorectal  
35  
36  
37 12 cancers, and in those with FIT (+/-), the rates were very low. Our results suggest that patients under  
38  
39  
40 13 50 years of age with 2 positive FITs might need to receive a higher priority for colonoscopy than  
41  
42  
43 14 those over 50 years with 1 positive FIT. There is some discussion as to whether colorectal cancer  
44  
45  
46 15 screening should be started for subjects under 50 years of age, in whom the incidence of colorectal  
47  
48  
49 16 cancer is quite low but is increasing.<sup>28</sup> If they were screened by 2-positive results from 2-sample  
50  
51  
52 17 FITs, the cost-benefit balance might be acceptable.

53  
54  
55 18 The present study cannot answer whether the 2-sample FIT is superior to the 1-sample quantitative  
56  
57  
58 19 FIT as a tool for organised colorectal cancer screening program. The 1-sample FIT is simpler and

1  
2  
3  
4 1 less expensive at the primary screening step. Careful and wide-range evaluations are necessary to  
5  
6  
7 2 select the best method, which should depend on the various conditions of the population. An  
8  
9  
10 3 advantage of the 2-sample FIT is based on the considerable discordance in FIT results between  
11  
12  
13 4 samples collected even from the same person. The result can sometimes change from 1 ng/mL of the  
14  
15  
16 5 first sample to 1000 ng/mL of the second sample on the next day (cutoff: 100 ng/mL = 20 µg Hb/g  
17  
18  
19 6 faeces, in the case of the OC Sensor method, Eiken Chemical Co., Ltd., Tokyo, Japan) by the next  
20  
21  
22 7 day. The 2-sample FIT may have advantages over the 1-sample FIT, even after adjusting the  
23  
24  
25 8 threshold, under some circumstances. On the other hand, for risk stratification, the appropriate  
26  
27  
28 9 secondary cutoff values for the 1-sample quantitative FIT need to be decided for each FIT kit. The  
29  
30  
31 10 2-sample FIT, using the established threshold for each FIT kit, has two possible results: 2-positive or  
32  
33  
34 11 1-positive result.

35  
36  
37 12 We propose that patients with 2-positive results should be prioritised for colonoscopy, especially  
38  
39  
40 13 when resources are limited. In addition, given the COVID-19 pandemic, patients are likely to  
41  
42  
43 14 hesitate to undergo colonoscopy. In such cases, they should be strongly encouraged to receive  
44  
45  
46 15 colonoscopy with high priority. It may be useful to stratify patients with symptoms in a primary care  
47  
48  
49 16 setting. In the setting of 1-sample FIT screening, our results suggest that secondary FIT administered  
50  
51  
52 17 to patients with a positive primary FIT result can help identify patients at higher risk for whom  
53  
54  
55 18 colonoscopy should not be delayed.

## 1 **Limitations and Strengths**

2 This study has several limitations. First, it was conducted at a single endoscopy unit; hence, the  
3 results cannot be generalised. However, the indications and quality of colonoscopy as well as the  
4 criteria for diagnosis were well controlled. Two-sample FIT-based colorectal screening has been  
5 conducted for many years throughout Japan. Our results could well represent the regular practice of  
6 colorectal screening in Japan. Second, the FIT kit brands and cutoff values for positivity were  
7 various and unknown in many cases that were referred from other medical institutions for  
8 colonoscopy. The guidelines for colorectal cancer screening in Japan only recommend the 2-sample  
9 FIT as standard, with no specific kits or cutoff values. As differences in FIT kit features and  
10 thresholds have been known to affect screening performance,<sup>29</sup> these variations are certainly a  
11 limitation of our study. However, a notable difference in the results between 2-positive and  
12 1-positive FIT groups shown in our study suggests a common trend irrespective of kits brand. Third,  
13 we did not assess the patients' symptoms in detail, as cancer detection rates were low in symptomatic  
14 patients without FIT evaluation. However, the symptoms in our patients were generally mild. In  
15 populations with more serious symptoms, they could also be useful to urge early colonoscopy.<sup>30</sup>  
16 Fourth, positive predictive values are highly associated with the expected prevalence of lesions in the  
17 study population. Our results are susceptible to bias due to heterogeneity among our patients, which  
18 is a limitation of our study design. However, based on our results, detection rates of more advanced  
19 tumours were excellent in patients with 2-positive results, whereas they were generally quite low in

1  
2  
3  
4 1 the other positive groups. Further, this trend was observed irrespective of age groups. Although the  
5  
6  
7 2 results could change according to the study population, we assume that higher risk for  
8  
9  
10 3 advanced-stage lesions in 2-positive FIT results is generally true for various populations.  
11  
12  
13 4

16 5 In conclusion, 2-positive results for 2 samples of FIT showed a much higher yield of advanced  
17  
18  
19 6 colorectal cancers than the 1-positive result, which also showed a higher yield than colonoscopy  
20  
21  
22 7 performed in patients with symptoms or with an associated history. The highest priority for  
23  
24  
25 8 diagnostic colonoscopy should be assigned to patients with 2-positive-FIT results.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
2. Segnan N, Patnick J, von Karsa L, eds. *European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis.* 1st ed. Luxembourg: Publications Office of the European Union; 2010.
3. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. *Am J Gastroenterol.* 2010;105(9):2017-2025.
4. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal Immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology.* 2017;152(5):1217-1237.
5. Issaka RB, Somsouk M. Colorectal Cancer Screening and Prevention in the COVID-19 Era [published online May 13, 2020]. *JAMA Health Forum.*
6. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. *Gut.* 2015;64(10):1637-1649.



- 1  
2  
3  
4 7. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical  
5  
6  
7 fecal occult blood test for detection of colorectal neoplasia. *Hepatogastroenterology*.  
8  
9  
10 1999;46(25):228-231.  
11
- 12  
13 8. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of  
14  
15  
16 samples and positivity cutoff. What is the best strategy for colorectal cancer screening? *Br J Cancer*.  
17  
18  
19 2009;100(2):259-265.  
20
- 21  
22 9. van Roon AH, Wilschut JA, Hol L, et al. Diagnostic yield improves with collection of 2  
23  
24  
25 samples in fecal immunochemical test screening without affecting attendance. *Clin Gastroenterol*  
26  
27  
28 *Hepatol*. 2011;9(4):333-339.  
29
- 30  
31 10. Cai S-R, Zhu H-H, Huang Y-Q, et al. Cost-effectiveness between double and single fecal  
32  
33  
34 immunochemical test(s) in a mass colorectal cancer screening. *Biomed Res Int*. 2016;2016:6830713.  
35
- 36  
37 11. Moosavi S, Enns R, Gentile L, et al. Comparison of one versus two fecal immunochemical  
38  
39  
40 tests in the detection of colorectal neoplasia in a population-based colorectal cancer screening  
41  
42  
43 program. *Can J Gastroenterol Hepatol*. 2016;2016:5914048.  
44
- 45  
46 12. Wieten E, de Klerk CM, Lansdorp-Vogelaar I, et al. A quarter of participants with advanced  
47  
48  
49 neoplasia have discordant results from 2-sample fecal immunochemical tests for colorectal cancer  
50  
51  
52 screening. *Clin Gastroenterol Hepatol*. 2020;18(8):1805-1811.  
53
- 54  
55 13. Toyoshima O, Hata K, Yoshida S, et al. New-generation chromoendoscopy may increase  
56  
57  
58 confidence in the DISCARD2 study. *Gut*. 2018;67(9):1742-1743.  
59  
60

- 1  
2  
3  
4 14. Toyoshima O, Yoshida S, Nishizawa T, et al. CF290 for pancolonoscopic chromoendoscopy  
5  
6  
7 improved sessile serrated polyp detection and procedure time: a propensity score-matching study.  
8  
9  
10 Endosc Int Open. 2019;7(8):E987-E993.  
11  
12  
13 15. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma  
14  
15  
16 detection during screening colonoscopy. *N Engl J Med*. 2006;355(24):2533-2541.  
17  
18  
19 16. Toyoshima O, Nishizawa T, Sakitani K, et al. Colonoscopy using back brace support belt: A  
20  
21  
22 randomized, prospective trial. *JGH Open*. 2020;4(3):441-445.  
23  
24  
25 17. Toyoshima O, Nishizawa T, Yoshida S, et al. Expert endoscopists with high adenoma  
26  
27  
28 detection rates frequently detect diminutive adenomas in proximal colon. *Endosc Int Open*.  
29  
30  
31 2020;8(6):E775-E782.  
32  
33  
34 18. Brierley JD, Gospodarowicz MK, Wittekind C, eds. UICC TNM classification of malignant  
35  
36  
37 tumours. 8th ed. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc.; 2017.  
38  
39  
40 19. Schlemper R, Riddell R, Kato Y, et al. The Vienna classification of gastrointestinal  
41  
42  
43 epithelial neoplasia. *Gut*. 2000;47(2):251-255.  
44  
45  
46 20. Ishihara S, Watanabe T, Akahane T, et al. Tumor location is a prognostic factor in poorly  
47  
48  
49 differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the  
50  
51  
52 colon. *Int J Colorectal Dis*. 2012;27(3):371-379.  
53  
54  
55 21. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of bowel  
56  
57  
58 cancer screening with a faecal immunochemical test: results from a pilot study within the national  
59  
60

1  
2  
3  
4 screening programme in England. *Gut* 2017;66(9):1631-44.  
5  
6

7 22. Clark G, Strachan JA, Carey FA, et al. Transition to quantitative faecal immunochemical  
8  
9 testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel  
10  
11 screening programme. *Gut* 2021;70(1):106-13.  
12  
13

14  
15 23. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult  
16  
17 blood test and total colonoscopy in the asymptomatic population. *Gastroenterology*.  
18  
19 2005;129(2):422-428.  
20  
21  
22

23  
24 24. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and  
25  
26 false-negative results from the fecal immunochemical test. *Clin Gastroenterol Hepatol*.  
27  
28 2013;11(7):832-838.  
29  
30  
31

32  
33 25. Yamaji Y, Majima K, Wada R, et al. Simulating positive predictive values in two-sample  
34  
35 fecal immunochemical test screening. *J Gastrointestinal Cancer Screen*. 2017;55(5):666-675. [in  
36  
37 Japanese with English abstract]. [https://www.jstage.jst.go.jp/article/jsgcs/55/5/55\\_666/\\_pdf/-char/ja](https://www.jstage.jst.go.jp/article/jsgcs/55/5/55_666/_pdf/-char/ja).  
38  
39  
40

41  
42 26. Loveday C, Sud A, Jones ME, et al. Prioritisation by FIT to mitigate the impact of delays in  
43  
44 the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling  
45  
46 study [published online August 29, 2020]. *Gut*.  
47  
48  
49

50  
51 27. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after  
52  
53 screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal  
54  
55 Cancer. *Gastroenterology*. 2012;143(3):844-857.  
56  
57  
58

- 1  
2  
3  
4 28. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk  
5  
6  
7 adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*.  
8  
9  
10 2018;68(4):250-281.  
11  
12  
13 29. Chapman CJ, Banerjea A, Humes DJ, et al. Choice of faecal immunochemical test matters:  
14  
15  
16 comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal  
17  
18  
19 cancer. *Clin Chem Lab Med* 2020;cclm-2020-1170.  
20  
21  
22 30. Suspected cancer: recognition and referral. NICE guideline [NG12]: NICE: National  
23  
24  
25 Institute for Health and Care Excellence, 2017.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TABLES

Table 1. Study patients.

|                              | Total          | Positive FIT   |                |                | Other than positive FIT |                |                          |
|------------------------------|----------------|----------------|----------------|----------------|-------------------------|----------------|--------------------------|
|                              |                | Total          | FIT (+/+)      | FIT (+/-)      | Total                   | Symptom        | Screening + surveillance |
| <b>No.</b>                   | 8724           | 1282           | 264            | 1018           | 7442                    | 1826           | 5616                     |
| <b>Age, mean (SD), years</b> | 53.7<br>(12.5) | 50.8<br>(12.4) | 52.7<br>(13.7) | 50.3<br>(11.9) | 54.2<br>(12.4)          | 49.2<br>(13.4) | 55.8 (11.6)              |
| <b>Male, n (%)</b>           | 4350<br>(49.9) | 613<br>(47.8)  | 144<br>(54.5)  | 469<br>(46.1)  | 3737<br>(50.2)          | 722 (39.5)     | 3015 (53.7)              |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

**Table 2. Detection rates of colorectal cancer based on the indication for colonoscopy.**

|   | Total | Positive FIT      |                    |                   | Other than positive FIT |                   |                          |
|---|-------|-------------------|--------------------|-------------------|-------------------------|-------------------|--------------------------|
|   |       | Total             | FIT (+/+)          | FIT (+/-)         | Total                   | Symptom           | Screening + surveillance |
| <b>No.</b>                                | 8724  | 1282              | 264                | 1018              | 7442                    | 1826              | 5616                     |
| <b>All cancers (including in situ), n</b> | 79    | 51                | 32                 | 19                | 28                      | 15                | 13                       |
| <b>Detection rate</b>                     | 0.9%  | 4.0% <sup>a</sup> | 12.1% <sup>b</sup> | 1.9% <sup>c</sup> | 0.4%                    | 0.8% <sup>d</sup> | 0.2%                     |
| <b>Invasive cancers, n</b>                | 37    | 25                | 22                 | 3                 | 12                      | 7                 | 5                        |
| <b>Detection rate</b>                     | 0.4%  | 2.0% <sup>a</sup> | 8.3% <sup>b</sup>  | 0.3%              | 0.2%                    | 0.4% <sup>e</sup> | 0.1%                     |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

<sup>a</sup>  $P < .001$ , Positive FIT vs. Other than positive FIT.

<sup>b</sup>  $P < .001$ , FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P = .02$ , FIT (+/-) vs. Symptom.

<sup>d</sup>  $P < .001$ , Symptom vs. Screening + surveillance.

<sup>e</sup>  $P = .01$ , Symptom vs. Screening + surveillance.

**Table 3. Colorectal cancer detection rates based on age and FIT positivity groups.**

|   | Age $\geq$ 50 years |                    |                   | Age <50 years |                    |           |
|---|---------------------|--------------------|-------------------|---------------|--------------------|-----------|
|   | Total               | FIT (+/+)          | FIT (+/-)         | Total         | FIT (+/+)          | FIT (+/-) |
| <b>No.</b>                                | 630                 | 140                | 490               | 652           | 124                | 528       |
| <b>All cancers (including in situ), n</b> | 35                  | 18                 | 17                | 16            | 14                 | 2         |
| <b>Detection rate</b>                     | 5.6% <sup>a</sup>   | 12.9% <sup>b</sup> | 3.5% <sup>c</sup> | 2.5%          | 11.3% <sup>b</sup> | 0.4%      |
| <b>Invasive cancers, n</b>                | 15                  | 12                 | 3                 | 10            | 10                 | 0         |
| <b>Detection rate</b>                     | 2.4%                | 8.6% <sup>b</sup>  | 0.6%              | 1.5%          | 8.1% <sup>b</sup>  | 0%        |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

<sup>a</sup>  $P=$ .006, Age  $\geq$ 50 years vs. Age <50 years.

<sup>b</sup>  $P<$ .001, FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P<$ .001, Age  $\geq$ 50 years vs. Age <50 years.

**Table 4. Features of colorectal cancers based on indication for colonoscopy.**

|   | Total        | Positive FIT             |            | Other than positive FIT |                          |
|---|--------------|--------------------------|------------|-------------------------|--------------------------|
|   |              | FIT (+/+)                | FIT (+/-)  | Symptom                 | Screening + Surveillance |
| <b>No.</b>  | 79           | 32                       | 19         | 15                      | 13                       |
| <b>Location (Proximal/Distal), n</b>              | 23/56        | 10/22                    | 5/14       | 1/14                    | 7/6 <sup>a</sup>         |
| <b>Size (SD), mm</b>                              | 26.1 (19.9)  | 31.2 (22.7) <sup>b</sup> | 17.4 (9.7) | 30.0 (20.4)             | 22.0 (19.8)              |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 42/12/8/15/2 | 10/7/4/10/1 <sup>c</sup> | 16/1/2/0/0 | 8/1/1/4/1               | 8/3/1/1/0                |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 74/4         | 30/2                     | 19/0       | 13/1                    | 12/1                     |

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT. "Proximal" indicates from the caecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. SD: standard deviation. "T stage" of the tumour was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma. One squamous cell carcinoma was excluded from this analysis.

<sup>a</sup>  $P=.046$ , Screening + Surveillance vs. the others.

<sup>b</sup>  $P=.004$ , FIT (+/+) vs. FIT (+/-).

<sup>c</sup>  $P<.001$ , FIT (+/+) vs. FIT (+/-).



## FIGURE LEGEND



### **Figure 1. Cancer detection rates stratified by T stages based on age and FIT positivity groups.**

T stage was classified according to the UICC TNM Classification.

FIT (+/+) had a higher percentage of invasive cancers than in FIT (+/-).

Abbreviation: FIT, faecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT.

For peer review only



**Supplementary Table 1. Details of the positive FIT groups**

|   | FIT (+/+)   | FIT (+/-)               | FIT (+)           | FIT (+/?)         |
|---|-------------|-------------------------|-------------------|-------------------|
| <b>No.</b>  | 264         | 1018                    | 136               | 287               |
| <b>Age, mean (SD), years</b>                      | 52.7 (13.7) | 50.3 (11.9)             | 48.3 (12.1)       | 51.2 (12.2)       |
| <b>Male, n (%)</b>                                | 144 (54.5)  | 469 (46.1)              | 65 (47.8)         | 119 (41.5)        |
| <b>All cancers (including in situ), n</b>         | 32          | 19                      | 2                 | 6                 |
| <b>Detection rate</b>                             | 12.1%       | 1.9% <sup>a</sup>       | 1.5% <sup>a</sup> | 2.1% <sup>a</sup> |
| <b>Invasive cancers, n</b>                        | 22          | 3                       | 0                 | 4                 |
| <b>Detection rate</b>                             | 8.3%        | 0.3% <sup>a</sup>       | 0.0% <sup>a</sup> | 1.4% <sup>a</sup> |
| <b>Age ≥50 years</b>                              |             |                         |                   |                   |
| <b>No.</b>  | 140         | 490                     | 54                | 145               |
| <b>All cancers (including in situ), n</b>         | 18          | 17                      | 2                 | 5                 |
| <b>Detection rate</b>                             | 12.9%       | 3.5% <sup>a</sup>       | 3.7%              | 3.4% <sup>b</sup> |
| <b>Invasive cancers, n</b>                        | 12          | 3                       | 0                 | 4                 |
| <b>Detection rate</b>                             | 8.6%        | 0.6% <sup>a</sup>       | 0.0% <sup>c</sup> | 2.8% <sup>c</sup> |
| <b>Age &lt;50 years</b>                           |             |                         |                   |                   |
| <b>No.</b>  | 124         | 528                     | 82                | 142               |
| <b>All cancers (including in situ), n</b>         | 14          | 2                       | 0                 | 1                 |
| <b>Detection rate</b>                             | 11.3%       | 0.4% <sup>a</sup>       | 0.0% <sup>b</sup> | 0.7% <sup>a</sup> |
| <b>Invasive cancers, n</b>                        | 10          | 0                       | 0                 | 0                 |
| <b>Detection rate</b>                             | 8.1%        | 0.0% <sup>a</sup>       | 0.0% <sup>c</sup> | 0.0% <sup>b</sup> |
| <b>Features of cancers</b>                        |             |                         |                   |                   |
| <b>Location (Proximal/Distal), n</b>              | 10/22       | 5/14                    | 1/1               | 0/6               |
| <b>Size (SD), mm</b>                              | 31.2 (22.7) | 17.4 <sup>b</sup> (9.7) | 9.0 (8.5)         | 36.5 (42.0)       |
| <b>T stage (Tis/T1/T2/T3/T4), n</b>               | 10/7/4/10/1 | 16/1/2/0/0              | 2/0/0/0/0         | 2/2/0/1/1         |
| <b>Histological subtype (Well+Mod/Por+Muc), n</b> | 30/2        | 19/0                    | 2/0               | 6/0               |

Abbreviation: FIT, fecal immunochemical test. FIT (+/+) indicates 2-positive results for the 2-sample FIT. FIT (+/-) indicates a 1-positive result for the 2-sample FIT. FIT (+) indicates a 1-positive result for the 1-sample FIT. FIT (+/?) indicates positive FIT results with unknown number of positivity. SD: standard deviation. "Proximal" indicates from the cecum to the transverse colon and "Distal" indicates from the descending colon to the rectum. "T stage" of the tumor was based on the UICC TNM Classification. "Well+Mod" indicates well- and moderately-differentiated adenocarcinoma. "Por+Muc" indicates poorly-differentiated and mucinous adenocarcinoma.

<sup>a</sup>  $P < .001$ , vs. FIT (+/+).

<sup>b</sup>  $P < .01$ , vs. FIT (+/+).

<sup>c</sup>  $P < .05$ , vs. FIT (+/+).

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

| Section/Topic                | Item # | Recommendation   | Reported on page #                         |
|------------------------------|--------|--|--|
| Title and abstract           | 1      | (a) Indicate the study’s design with a commonly used term in the title or the abstract   | P1 line3-5, P4 line6-7                     |
|                              |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | P4 line6-P5 line6                          |
| <b>Introduction</b>          |        |  |  |
| Background/rationale         | 2      | Explain the scientific background and rationale for the investigation being reported   | P6 line2-16                                |
| Objectives                   | 3      | State specific objectives, including any prespecified hypotheses   | P6 line17-P7 line3                         |
| <b>Methods</b>               |        |  |  |
| Study design                 | 4      | Present key elements of study design early in the paper  | P7 line6-P8 line4                          |
| Setting                      | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | P7 line7-8                                 |
| Participants                 | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants  | P7 line7-P8 line4                          |
| Variables                    | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | P10 line2-7                                |
| Data sources/<br>measurement | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | P7 line10-P8 line4,<br>P8 line15-P9 line19 |
| Bias                         | 9      | Describe any efforts to address potential sources of bias  | P7 line16-18, P10<br>line6-7               |
| Study size                   | 10     | Explain how the study size was arrived at  | P7 line7-9                                 |
| Quantitative variables       | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | P9 line10-19                               |
| Statistical methods          | 12     | (a) Describe all statistical methods, including those used to control for confounding  | P10 line10-15                              |
|                              |        | (b) Describe any methods used to examine subgroups and interactions  | P10 line6-7, 10-15                         |
|                              |        | (c) Explain how missing data were addressed  | N.A.                                       |
|                              |        | (d) If applicable, describe analytical methods taking account of sampling strategy   | N.A.                                       |
|                              |        | (e) Describe any sensitivity analyses  | N.A.                                       |
| <b>Results</b>               |        |  |  |

|                          |     |  |                                       |
|--------------------------|-----|--|---------------------------------------|
| Participants             | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | P11 line3-11                          |
|                          |     | (b) Give reasons for non-participation at each stage   | P11 line4-6                           |
|                          |     | (c) Consider use of a flow diagram   | N.A.                                  |
| Descriptive data         | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | P11 line6-11                          |
|                          |     | (b) Indicate number of participants with missing data for each variable of interest  | N.A.                                  |
| Outcome data             | 15* | Report numbers of outcome events or summary measures   | P11 line14-19                         |
| Main results             | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | P12 line1-9                           |
|                          |     | (b) Report category boundaries when continuous variables were categorized  | N.A.                                  |
|                          |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | N.A.                                  |
| Other analyses           | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | P12 line16-P13 line8,<br>P14 line4-10 |
| <b>Discussion</b>        |     |  |                                       |
| Key results              | 18  | Summarise key results with reference to study objectives   | P14 line13-19                         |
| Limitations              | 19  | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   | P17 line16-P18<br>line18              |
| Interpretation           | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | P19 line1-4                           |
| Generalisability         | 21  | Discuss the generalisability (external validity) of the study results  | P17 line16-P18<br>line18              |
| <b>Other information</b> |     |  |                                       |
| Funding                  | 22  | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | P2 line14-15                          |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).